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Glucose homeostasis 
Glucose levels are tightly regulated in the human body. Even after food-intake or 
fasting, glucose levels remain relatively stable. The major organs involved in 
regulating glucose levels are the pancreas, liver, skeletal muscle and adipose 
tissue. In the pancreas beta-cells are present, which are part of the Islets of 
Langerhans. Triggered by increased glucose levels these beta-cells will secrete 
insulin. The main target tissues of insulin action are liver, skeletal muscle and 
adipose tissue. Insulin promotes uptake of glucose from the periphery in adipoytes 
and muscle. The liver is involved in gluconeogenesis in which glucose is 
synthesized from C-3 compounds such as lactate, glycerol and pyruvate, derived 
from amino acids and by glycolysis. The rate limiting step of gluconeogenesis is the 
activity of the enzyme phosphoenolpyruvate carboxykinase (PEPCK). In the 
presence of high insulin levels, PEPCK expression is suppressed, yielding a 
decrease in gluconeogenesis. In addition, in the liver and muscle insulin regulates 
the balance between glycogenesis, which forms glycogen from glucose and 
glycogenolysis, yielding glucose from glycogen breakdown. Glycogen is a 
polysaccharide chain, which is an efficient form of glucose storage. In the presence 
of high insulin and low glucagon levels (the latter produced by pancreatic alpha-
cells within the islets of Langerhans), glucose is converted into glycogen, whereas 
in situations with low insulin and high glucagon concentrations, glycogen is 
degraded into glucose. Furthermore, insulin increases glucose uptake 
predominantly by skeletal muscle and adipose tissue resulting in a drop of blood 
glucose levels. After uptake, excess of glucose is either stored as glycogen 
(muscle) or converted into triglyceride (adipocytes). In addition it may be degraded 
into lactate via a process called glycolysis and further into CO2 via the tricarboxylic 
acid cycle and oxidative phosphorylation when metabolic energy is needed. These 
degradations are coupled to ATP synthesis as described in more detail later in this 
introduction. Moreover, insulin inhibits lipolysis and increases triglyceride synthesis 
in the adipose tissue. These processes are reviewed in references 1-3. 
Taken together, increased glucose levels will result in insulin secretion by beta-
cells leading to decreased gluconeogenesis by the liver and increased glucose 
uptake by skeletal muscle and adipose tissue. In addition glycogenesis is 
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increased while glycogenolysis is decreased. Together, this will result in a drop in 
glucose levels and subsequently decreased insulin secretion preserving the 
physiological glucose levels around 5 mmol/L. This is important because high 
levels of glucose (hyperglycaemia) cause damage to blood vessels and nerves by 
chemical modification of proteins, while low levels of glucose (hypoglycaemia) can 
results in dysfunction of the brain leading to coma and death (1-3). 
 
Diabetes 
Diabetes Mellitus is a common disease and its prevalence is rapidly increasing. It is 
expected that the global burden of diabetes mellitus is 300 million people in 2025, 
while this was 150 million in 2000 (4). The disease is divided in several subtypes; 
type 1 diabetes and type 2 diabetes being the most common forms. Both subtypes 
are characterized by chronic hyperglycaemia defined as having fasting plasma 
glucose (FPG) concentrations above 7.0 mmol/L (4-6). The prevalence of 
especially type 2 diabetes exhibits an explosive growth in societies with a western 
life style. 
Long term hyperglycaemia can lead to several complications like micro-vascular 
complications in the eye and kidney and neurologic complications. In addition, type 
2 diabetes is strongly associated with an increased risk for cardiovascular disease 
due to macro-vascular complications. The latter is predominantly responsible for 
the increased mortality (6-9). Next to type 1 diabetes and type 2 diabetes several 
other specific subgroups of diabetes exist like Maturity Onset Diabetes of the 
Young (MODY) and Maternally Inherited Diabetes and Deafness (MIDD). Both are 
high penetrance, monogenic forms of the disease, caused by single nucleotide 
polymorphisms (SNP). Another diabetes subtype is Gestational Diabetes Mellitus 
(GDM), which occurs in pregnant women. Women who suffered from GDM are 
more likely to develop type 2 diabetes later in life (6). Latent Autoimmune Diabetes 
in Adults (LADA) is yet another subtype of diabetes mellitus. This syndrome 
associates with autoimmunity against glutamic acid decarboxylase. The disease is 
often diagnosed as type 2 diabetes because of its late onset (10). 
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Type 1 diabetes and type 2 diabetes  
Type 1 diabetes is characterized by an absolute insulin deficiency, most commonly 
caused by auto-immune destruction of insulin producing beta-cells in the pancreas 
(6). The disease has an early onset with a peak at 12 years of age. Patients are 
fully dependent on exogenous insulin, administered by injections (11). There are 
genetic risk factors, determining the vulnerability to develop type 1 diabetes. HLA 
haplotypes account for ~50% of the familial clustering of type 1 diabetes. Genome 
wide association studies (described in more detail later in this introduction) have 
now increased this number to 12 loci (12;13).  
Type 2 diabetes is a disease with a gradual onset, mostly later in life. In most 
cases the disease manifests above 40 years of age with a peak at 60 years. Type 
2 diabetes patients show a relative rather than an absolute insulin deficiency in 
combination with an insulin resistant state in which target tissues have an impaired 
reaction on insulin. When the beta-cells cannot produce sufficient amounts of 
insulin to correct for the increased demand, hyperglycaemia will develop. 
Patients are initially treated by diet and life style interventions, aimed at reducing 
the level of insulin resistance by weight loss and enhanced muscle glucose uptake, 
independent of insulin, by physical exercise. When this approach fails 
pharmaceutical treatment is initiated. Commonly used drugs include metformin, 
which suppresses hepatic glucose production and sulfonylurea which triggers 
additional insulin secretion by pancreatic beta-cells independent of glucose. 
Gradually, the severity of the disease progresses which can lead to insulin 
dependency (6;14). 
Several risk factors for type 2 diabetes are known, like ageing, overweight, low 
levels of physical activity and genetic variation. The increased prevalence of type 2 
diabetes is most likely caused by western life style, which means overfeeding and 
too little exercise. Which genes are involved in the onset of type 2 diabetes, is not 
completely clear (14;15). Because type 2 diabetes is a very heterogeneous disease 
it is difficult to make a good estimation of the heritability, but a Danish twin study 
has resulted in an estimation up to 72%, depending on the applied model (16). In 
theory, genetic risk factors may directly affect the risk for type 2 diabetes, e.g. by 
modulating the capacity of the beta cells to secrete insulin or by inducing insulin 
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resistance. Genetic variation may also indirectly affect the risk for type 2 diabetes, 
e.g. by affecting the satiety feeling after food intake as excessive food intake 
enhances the risk for diabetes. This distinction is important when interpreting data 
from genetic studies 
 
Genetics of type 2 diabetes 
In the last decades efforts were made to identify type 2 diabetes genes, using the 
candidate gene approach and linkage studies in which the transmittance of an 
allele or locus is examined in families with multiple cases of type 2 diabetes. When 
applying candidate gene studies, the genes to be examined are selected based on 
data on their direct or indirect involvement in glucose homeostasis. Genetic 
variation, most commonly single nucleotide polymorphisms (SNPs), in these genes 
is measured in a sample of subjects with and without type 2 diabetes. Such sample 
could be a population based study, which is a random selection of subjects from a 
population. The allele frequency of a SNP is than compared between healthy 
participants and type 2 diabetes patients in the selected population. More 
commonly case-control studies are used, which are selected groups of control and 
type 2 diabetes subjects. Matching can be performed e.g. for age and BMI as these 
are major additional determinants for type 2 diabetes susceptibility. The allele 
frequency of the SNP in the type 2 diabetes group is compared to the control 
group. If the allele frequency is enriched in the type 2 diabetes group, the allele is 
assumed to predispose for type 2 diabetes susceptibility. The benefit of a case-
control study compared to a population based study is that it is a better controlled 
experiment. This approach is well powered for common SNPs with a Minor Allele 
Frequency (MAF) above 5% even if the penetrance is low, as long as the selected 
population is of suitable size. A different approach is the linkage study. In linkage 
studies SNPs or loci are measured in family pedigrees and the transmittance of a 
risk allele or risk loci to type 2 diabetes family members is analyzed. The latter 
approach is more applicable for rare variants with high penetrance (minor allele 
frequency (MAF) below 1%), but is underpowered for SNPs with a low penetrance. 
Both approaches require replication of novel findings in additional populations. It is 
important that a replication study is of suitable size in order to obtain sufficient 
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statistical power. Differences in for instance ethnicity of participants in the studies 
could result in a false negative replication. Therefore, a replication study should be 
well designed. 
The linkage studies were quite successful in identifying the genes for the MODY 
subtypes and for MIDD, which were found to be monogenetic diseases, caused by 
SNPs with a high penetrance. These approaches had, however, very little success 
in identifying the genes for common type 2 diabetes. Only three type 2 diabetes 
genes were identified via case-control studies: Peroxisome Proliferator-activated 
Receptor Gamma (PPARG), Calpain10 (CAPN10) and Potassium inwardly-
rectifying channel, subfamily J, member 11 (KCNJ11). The effect of these genes on 
the risk for type 2 diabetes in the general population was found to be small (17-21). 
The only gene which was associated with type 2 diabetes with a higher impact was 
Transcription Factor 7-like2 (TFC7L2) (OR ~1.35), which was found in an Icelandic 
population and widely replicated in various ethnic populations. This gene was 
identified by extensive analysis of a genomic region which showed evidence for 
linkage with type 2 diabetes in previous studies and therefore its identification was 
not the result from a classical candidate gene study (21;22).  
More progression in identifying type 2 diabetes susceptibility genes was made 
when genome wide association studies (GWAS) were developed. Using dense 
arrays with up to 500,000 SNPs a large proportion of genetic variation in the 
human genome was covered. Because the GWAS approach covers up to 500,000 
SNPs randomly spread through the human genome, the outcome is not biased by 
candidate gene hypothesis. However, the statistical drawback of testing 500,000 
SNPs is that the p-value has to be corrected for 500,000 tests. Using Linkage 
Disequilibrium (LD) even more SNPs can be assessed. If there is no recombination 
hotspot between SNPs, they will not be separated by recombination during meiosis 
and therefore be in high LD and inherited together. So, a group of SNPs which are 
in between two recombination hotspots will be in high LD. Such group of SNPs is 
called an LD-block. Using this knowledge one SNP can be predicted by genotyping 
of several others. Therefore, association of a SNP can be tested without directly 
genotyping the SNP. This strategy is called imputation. Data of linkage between 
SNPs is available on the HapMap database (www.HAPMAP.org) (23-25). Using 
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this strategy it is currently possible to test the association of up to 2,000,000 SNPs 
with type 2 diabetes from GWAS data. The p-value has to be corrected for 
2,000,000 tests when this strategy is applied and only a p-value smaller then 
2.5x10-8 can be considered as statistical significant. In order to reach such small p-
values very large study samples have to be used consisting of up to 50,000 
participants and even more.  
GWAS allows the identification of common SNPs that have a relatively low effect 
on type 2 diabetes susceptibility. However, it does not allow the detecting of rare 
and low frequency SNPs (MAF < 5%) with a modest effect on type 2 diabetes 
susceptibility. These studies are underpowered to detect such associations. 
Moreover, the coverage of low frequency and rare variation on GWAS genotyping 
chips is relatively low and much variation will therefore be missed. 
After several GWAS and a meta-analysis of three of these, the list of known type 2 
diabetes loci was expanded to 20, all with marginal effect sizes (OR 1.05 – 1.35) 
(21;26-32). Most of the newly identified SNPs are not located within the introns or 
exons of a gene and the pathogenic mechanism of associated SNPs is often 
unknown. If there is a suggested mechanism, it is mostly involved in decreased 
insulin secretion via an impaired beta-cell function. Remarkably, only one gene was 
identified as an insulin resistance gene (PPARG). This gene controls fatty acid 
metabolism and by that, indirectly insulin resistance. Insulin resistance was 
considered a major candidate pathway to be involved in the pathogenesis of type 2 
diabetes (table 1).  
The development of GWAS, during the preparation of this thesis, has dramatically 
changed the approach of genetic association studies. Therefore, my PhD-project 
starts with ‘old-fashioned’ candidate gene studies and is expanded with GWAS 
data, which came available after completion of our association studies.  
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Table 1. Confirmed type 2 diabetes susceptibility loci 
Gene (nearest) Strategy Mechanism Location 
PPARG Candidate gene 
Insulin sensitivity/ 
lipid metabolism 
Exon 
CAPN10 Linkage Glucose transport Intron 
KCNJ11 Candidate gene beta-cell function Exon 
TCF7L2 Candidate region beta-cell function Intron 
CDKAL1 GWAS beta-cell function Intron 
CDKN2A/B GWAS beta-cell function Intergenic 
HHEX/IDE GWAS beta-cell function Intergenic 
SLC30A8 GWAS beta-cell function Exon 
IGF2BP2 GWAS beta-cell function Intron 
WFS1 Candidate gene Unknown Intron 
TCF2 GWAS Unknown Intron 
FTO GWAS Obesity Intron 
NOTCH2 GWAS Unknown Intron 
ADAMTS9 GWAS Unknown Intergenic 
THADA GWAS Unknown Exon 
TSPAN8/LGR5 GWAS Unknown Intergenic 
CDC123/CAMK1D GWAS Unknown Intergenic 
JAZF1 GWAS Unknown Intron 
KCNQ1 GWAS beta-cell function Intron 
MTNR1B GWAS beta-cell function Intron 
Confirmed type 2 diabetes loci. OR ranging between 1.05 and 1.35. 
Adapted from Ridderstrale M et al, Mol.Cell Endocrinol (2009) (21). 
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Scope of the thesis 
The aim of this thesis was to elucidate the role of genetic variation in type 2 
diabetes susceptibility and related traits, in particular in genes involved in 
mitochondrial function. The experimental part of this thesis is divided in three parts. 
 
1. Nuclear encoded mitochondrial proteins: In the first part (chapters 2 
and 3) we have examined the relation between SNPs in nuclear encoded 
mitochondrial candidate genes and the risk for type 2 diabetes. We 
selected these mitochondrial targeted genes because we hypothesized 
that mitochondrial function is associated with type 2 diabetes, as described 
in this section. 
2. Mitochondrial DNA content and type 2 diabetes: In this part (chapter 4) 
we have investigated whether mitochondrial DNA content is associated 
with the risk for type 2 diabetes. 
3. Genes regulating fasting plasma glucose concentrations: In this part 
(chapter 5) we have analyzed the association of four combined fasting 
plasma glucose genes with glucose levels and type 2 diabetes 
susceptibility. 
 
The main topic is genetics of type 2 diabetes. The first two parts describe the role 
of mitochondria in type 2 diabetes; with a distinct focus on candidate genes (part 1) 
and mitochondrial DNA content (part 2). The third part does not focus on 
mitochondria, but describes cytosolic targeted genes influencing FPG levels. 
 
Finally the results obtained during this PhD-project are summarized and discussed 
in chapter 6. 
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Part1: Nuclear encoded mitochondrial proteins 
 
Mitochondria and energy homeostasis 
Mitochondria are the organelles in cells which are responsible for most of the 
adenosine triphosphate (ATP) production. Furthermore, they play a role in 
oxidative removal of fatty acids and of metabolites from amino acids. They are also 
involved in apoptosis. Because mitochondria have a crucial role in ATP production, 
cells requiring high levels of ATP like cardiac and skeletal muscle, neurons and 
beta-cells show a high mitochondrial density. Mitochondria have their own genome, 
which encodes for only a small fraction of mitochondrial components. It is 
estimated that a mitochondrion contains ~1500 different proteins. Only 13 of these 
are encoded by the mitochondrial genome, the remaining are nuclear encoded. In 
addition, the mitochondrial genome encodes for 2 rRNAs and 20 tRNAs (33;34). 
The mitochondrial genome is described in more detail in part 2 of this introduction. 
 
Oxidative Phosphorylation 
Cells take up glucose by different glucose transporters. Only muscle and 
adipocytes contain Glut4 transporters which are translocated to the cell membrane 
in response to insulin. In the cytosol glucose is metabolized into pyruvate via 
glycolysis. Pyruvate is transported into the mitochondria where it is further 
converted into CO2 by the Tricaboxylic acid cycle (TCA cycle). This cycle yields 
hydrogens in form of Nicotinamide Adenine Dinucleotide (oxidized form) (NADH) 
and Flavin Adenine Dinucleotide reduced (FADH2). These hydrogens are oxidized 
to H2O and the energy that is released by this oxidation is converted into chemical 
energy in form of ATP. This conversion is performed by the respiratory chain, 
which consists of 5 enzyme complexes, embedded in the mitochondrial inner 
membrane. The electrons flowing from H to O during the oxidation of NADH and 
FADH2 enter the respiratory chain at complex 1 in case of NADH and at complex 2 
in case of FADH2 oxidation. At complex 4 the electrons are transferred onto 
oxygen. The flow of electrons through the respiratory chain is coupled to a proton 
pumping outwards the mitochondrial matrix by complex I, III and IV. This results in 
formation of a proton gradient with excess of protons at the outside of the inner 
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mitochondrial membrane. The back flow of protons through complex 5 drives the 
synthesis of ATP from adenosine diphosphate (ADP) (35-39). This process is 
called oxidative phosphorylation and is shown in figure 1. Normally, the respiratory 
chain is not active, even when NADH, FADH2 and oxygen are present. Only when 
ADP is generated by catabolic activity, the increased ADP level activates the 
respiratory chain. Thus, cells can only oxidize glucose, fatty acids and amino acids 
when ADP is generated by metabolic activity. Activation of the respiratory chain is 
coupled to conversion of ADP into ATP. In addition, mitochondria can exist in an 
uncoupled state. In this situation, protons flow back into the mitochondrial matrix, 
independent of ATP synthesis, with generation of heat as result. By that, 
uncoupled mitochondria can oxidize large amounts of fuel. Uncoupling proteins 
and chemical agents like dinitrophenol and high concentrations of fatty acids 
induce mitochondrial uncoupling. 
The complexes from the respiratory chain consist of ~90 subunits encoded by both 
the nuclear and mitochondrial genome. Since the mitochondrial genome encodes 
for only 13 of these subunits the majority of subunits are encoded by the nuclear 
genome (37). 
 
Insulin secretion and mitochondria 
In the pancreatic beta-cell, mitochondria play a key role in insulin secretion. Human 
beta-cells express high Km Glut2 transporters, which are present at the cell 
membrane and transport glucose into the cytosol. Glucose is phosphorylated into 
glucose-6-phosphate by a beta cell specific hexokinase, called glucokinase. This is 
also a high Km enzyme (40-42). Subsequently, glucose-6-phosphate is further 
Figure 1. Oxidative phosphorylation by the respiratory chain 
 
Complexes I – V are shown, embedded in the inner mitochondrial membrane. These complexes 
generate a proton flow directed outwards the mitochondrion, resulting in ATP synthesis by complex V. 
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metabolized resulting in the synthesis of ATP via processes described in the 
previous section. The presence of two high Km enzymes at the entrance of this 
glycolytic pathway makes that the flux through this pathway is very sensitive to 
variations in glucose concentrations around the physiological concentration of 
5mmol/L (40;41). Therefore, variations in the ATP/ADP ratio in the cytoplasm 
depends on variations in the glycemic state. An increase in plasma glucose levels 
will increase the ATP/ADP ratio. An increased ATP/ADP ratio inhibits the ATP 
sensitive potassium channel, resulting in depolarization of the cell membrane. This 
activates the voltage-dependent calcium channel (VDCC) leading to an increased 
Ca2+ concentration in the cytoplasm, which is the main trigger for insulin secretion 
by fusion of insulin granules with the cell membrane (38;42). This process is shown 
in figure 2. Mitochondrial dysfunction could lead to an impaired glucose induced 
insulin secretion and subsequently type 2 diabetes. 
 
Figure 2. Glucose stimulated insulin secretion 
Glucose is transported into the beta-cell and processed into pyrovate. This enters the mitochondrion 
and is further processed into ATP, which is the main trigger for insulin secretion 
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Insulin resistance and mitochondria 
Mitochondria are also involved in the oxidation of fatty acids. This process is called 
beta-oxidation and degrades fatty acids into acetyl-CoA, which is subsequently 
oxidized through the TCA cycle. In physically active muscle, in which large 
amounts of ADP are generated, fatty acids are the main fuel for ATP-synthesis. 
Fatty acids normally induce insulin resistance in muscle cells when insulin-
stimulated glucose uptake is considered. This physiological adaptation process 
ensures that during fasting, when carbohydrate is scarce and fatty acids are 
generated by lipolysis in adipocytes, the physically active muscle uses fatty acids 
for energy supply, so that sufficient glucose remains available to provide the brain 
with energy since the brain uses predominantly glucose as fuel. 
An inherited defect in mitochondria is often associated with triglyceride deposits in 
muscle, suggesting impaired removal of fatty acids. A similar situation is observed 
in HIV-patients treated with Highly Active Anti Retroviral Therapy containing 
nucleoside analogues, in which mitochondrial DNA content is decrease (43;44). 
This excess of fatty acids contributes to insulin resistance of muscle and liver, a 
situation also seen in type 2 diabetes. By this mechanism a mitochondrial 
dysfunction may contribute to the development of insulin resistance and type 2 
diabetes (45-47). Furthermore, fatty acids are toxic to pancreatic beta-cells leading 
to a decline in insulin secretory capacity.  
 
Aim of Part 1 
Evidence is accumulating that mitochondrial dysfunction is a risk factor for the 
onset of type 2 diabetes. It has been shown that mitochondrial encoded enzymes 
of the oxidative phosphorylation are down regulated in type 2 diabetes patient 
muscle and these muscles have an impaired bioenergetic capacity (48;49). As 
described above, proper mitochondrial function is involved in both insulin secretion 
and insulin sensitivity. Alterations in these processes are the hallmarks of type 2 
diabetes. Relatively rare mutations in the mitochondrial DNA are shown to be 
associated with MIDD in part through a decreased insulin secretion (50;51). 
Furthermore, it has been shown that insulin resistant offspring of type 2 diabetes 
patients have an impaired mitochondrial activity. However, common SNPs in the 
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mitochondrial genome are not found to be associated with type 2 diabetes (52;53). 
Since the majority of mitochondrial proteins are encoded by the nuclear genome 
and translocated to the mitochondria, we hypothesized that defects in nuclear 
encoded mitochondrial proteins may be associated with type 2 diabetes. The aim 
of this part is: 
 
Analyzing the association of nuclear encoded mitochondrial targeted genes 
with type 2 diabetes susceptibility. 
 
In chapter 2 I describe our search for an association of various SNPs in the LARS2 
gene with type 2 diabetes. The protein encoded by this gene is involved in 
mitochondrial protein synthesis. It encodes the charging enzyme for the 
mitochondrial leucyl-tRNA(UUR). A mutation in the mitochondrial leucyl-
tRNA(UUR) gene can result in MIDD, but also mitochondrial myopathy, 
mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes 
(MELAS) and chronic progressive external ophthalmoplegia (CPEO) (50;54). A 
particular polymorphism in the LARS2 gene was previously found to be associated 
with type 2 diabetes (55). I investigated potential associations between several 
SNPs in LARS2 with type 2 diabetes in various cohorts from the Netherlands, UK, 
Denmark Sweden and Finland.  
In chapter 3 we have analyzed a selection of 13 candidate genes, all encoding 
mitochondrial proteins, for association with type 2 diabetes in the Netherlands and 
putative associations are replicated in cohorts from the Netherlands and Denmark. 
These candidate genes were selected from four clusters regarded essential for 
correct mitochondrial protein synthesis and biogenesis: aminoacyl tRNA 
synthetases, translation initiation factors, tRNA modifying enzymes and 
mitochondrial DNA transcription and replication. 
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Part 2: mitochondrial DNA content and type 2 diabetes 
 
Mitochondrial DNA 
As described in part 1 of this introduction, mitochondria have their own genome. 
This circular genome is approximately 16.6 kb in length and encodes for 13 genes 
of the oxidative phosphorylation, 2 rRNAs and 20 tRNAs (figure 3). Mitochondrial 
DNA (mtDNA) is predominantly maternally inherited. The quantity of mtDNA, the 
so-called mtDNA content, varies between different cell types. Cells contain 
approximately 1000 – 10,000 mtDNA copies (37;56). Mitochondrial activity in 
human fibroblasts declines upon aging, probably by accumulating somatic 
mutations in their DNA (57;58).  
Figure 3. Map of mitochondrial DNA 
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Mitochondria have their own DNA of ~16.6 kb, encoding for all tRNAs, 2 rRNAs and 13 
subunits for the oxidative phosphorylation. 
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Replication of mitochondrial DNA 
Replication of mtDNA is not dependent on cell division, but there is continuous 
mtDNA turn-over. Mitochondrial DNA is synthesized by DNA polymerase gamma 
(POLγ), a RNA-dependent DNA polymerase. This enzyme consists of 2 subunits, 
POLγA and POLγB. The proteins replicative mitochondrial helicase (TWINKLE) and 
mitochondrial Single-Stranded DNA-Binding protein (mtSSB) are responsible for 
unwinding and stabilizing of the mtDNA respectively (56;59-62). Mice expressing a 
proof reading defective POLγA, are characterized by accumulation of point 
mutations and deletions in the mtDNA, resulting in decreased life span and aging 
phenotypes like weight loss, hear loss and osteoporosis (63). 
 
Transcription of mitochondrial DNA 
Transcription of mtDNA is directed from two promotor sites, the Heavy Strand 
Promotor and Light Strand Promotor. Transcription is performed by the 
Mitochondrial RNA Polymerase (POLRMT). POLRMT forms a complex with the 
Mitochondrial Transcription Factor A (TFAM) and one of the two other transcription 
factors; Mitochondrial Transcription Factor B1 (TFB1M) or Mitochondrial 
Transcription factor B2 (TFB2M), which play important roles in DNA binding, 
unwinding, and prevention of RNA/DNA hybrid formation. After transcription, the 
mRNA is processed into proteins by the mitochondrial protein synthesis machinery 
consisting of nuclear encoded proteins and two mtDNA encoded rRNAs (56;64-66). 
 
Aim of Part 2 
As described in part1, mitochondrial function is altered in type 2 diabetes patients. 
Whether this is a cause or consequence is largely unknown. It has been shown 
that patients treated with highly active antiretroviral therapy have 30-50% 
decreased mtDNA content and are at increased risk for developing diabetes and 
the metabolic syndrome. Furthermore, a reduction of peripheral fat and 
development of central obesity is observed (44;67). This indicates that a reduction 
in mtDNA content is rather a cause than consequence of type 2 diabetes 
development. It has also been shown that mitochondrial content declines during 
aging in pancreatic islets and decreased mitochondrial content in beta-cells is 
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associated with decreased insulin secretion (68;69). Furthermore, a small study 
showed evidence that low mtDNA content in blood precedes the development of 
type 2 diabetes, further suggesting that mtDNA content may contribute to the 
development of type 2 diabetes (70). In a twin study it has been observed that 
mtDNA content is higher correlated in monozygotic twin pairs, compared to 
dizygotic twin pairs in blood, indicating that regulation of mtDNA content has a 
genetic component (71). Another study showed that this heritability might be linked 
with a genomic region on chromosome 10q (72). Taken together variation in the 
mtDNA content is a plausible candidate to modulate the risk for type 2 diabetes. 
The aim of this part is: 
 
Analysis of the heritability of mitochondrial DNA content in different tissues 
in relation to the risk for type 2 diabetes. 
 
In chapter 4 the heritability of mtDNA content is examined, using monozygotic and 
dizygotic twins, derived from the Dutch Twin Register. Mitochondrial DNA content 
is analyzed in samples obtained by buccal swabs. These cells represent a more 
homogenous cell sample compared to whole blood which was used in other 
studies. Furthermore, the association between mtDNA content and the onset of 
type 2 diabetes is examined in a case control study in the Netherlands and in two 
prospective studies from the Netherlands and Sweden. 
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Part3: Genes regulating fasting plasma glucose concentrations 
Plasma glucose levels are tightly regulated. Despite fluctuations in food intake and 
physical exercise, the variation in plasma glucose is limited. Deregulation of the 
glucose homeostasis may lead to hyperglycemia, which is the major hallmark of 
type 2 diabetes. Variation of FPG levels within healthy limits (FPG < 7 mmol/L) is 
clinical important as it has been found that FPG levels in the higher region of the 
healthy range result in an elevated risk for heart disease and type 2 diabetes later 
in life (8;73-76). Furthermore, FPG levels in pregnant women are an important 
predictor of the offspring birth weight, which is associated with the development of 
type 2 diabetes later in life of the offspring (77;78). FPG levels are approximately 
50% genetically determined (79). Therefore, a genetic predisposition for increased 
FPG levels may also represent an elevated risk for type 2 diabetes. A main 
component of the glucose sensing system, controlling FPG, consist of the 
pancreatic Glut2-Glucokinase system and its downstream pathway (80). 
 
The aim of this part of my thesis is: 
 
To analyze the effect of known FPG genes on FPG levels and subsequent 
risk for type 2 diabetes. 
 
The results of this part are described in chapter 5. Using a population based study 
in the Netherlands we examined the effects of known FPG genes on several 
clinical variables like FPG and HbA1C. Next we used a case-control study from the 
same region in the Netherlands to investigate the combined effect of these 
established FPG genes on type 2 diabetes risk. 
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Abstract 
Aims/hypothesis  
LARS2 has been previously identified as a potential type 2 diabetes susceptibility 
gene through the low frequency (LF) H324Q (rs71645922) variant (MAF 3.0%). 
However, this association did not achieve genome-wide levels of significance. The 
aim of this study was to establish the true contribution of this variant and common 
variants in LARS2 (MAF >5%) to type 2 diabetes risk.  
Methods 
We combined genome-wide association study (GWAS) data (n=10128) from the 
DIAGRAM consortium, with independent data derived from a tagging SNP 
approach in Dutch individuals (n=999), and took forward two SNPs of interest for 
replication in up to 11163 Dutch subjects. In addition, because inspection of the 
GWAS data identified a cluster of LF variants with evidence of type 2 diabetes 
association, we attempted replication of rs9825041 (a proxy for this group) and the 
previously identified H324Q variant in up to 35715 subjects of European descent.  
Results 
No association of the common SNPs in LARS2 with type 2 diabetes was found. 
Our replication studies for the 2 LF variants, rs9825041 and H324Q failed to 
confirm an association with type 2 diabetes in Dutch, Scandinavian and UK 
samples (OR 1.03 (0.95-1.12), p=0.45, n=31962 and OR 0.99 (0.90-1.08), p=0.78, 
n=35715 respectively).  
Conclusion 
In this study, the largest study examining the association of sequence variants in 
LARS2 with type 2 diabetes susceptibility we find no evidence to support previous 
data indicating a role in type 2 diabetes susceptibility. 
Chapter 2 
 
37 
Introduction 
Changes in mitochondrial function are observed in patients with type 2 diabetes 
and their first degree relatives. Previous studies have indicated that genes involved 
in oxidative phosphorylation are down regulated in the muscle cells of type 2 
diabetes patients (1). Furthermore, the muscle mitochondria from patients with type 
2 diabetes have an impaired bioenergetic capacity (2). Mitochondria also play an 
important role in insulin secretion and sensitivity (3;4). Previously, our group has 
shown that a mutation in the mitochondrial DNA encoded tRNA-Leu(UUR) gene is 
associated with maternally inherited diabetes and deafness (5). In addition, an 
H324Q (rs71645922) variant in the nuclear encoded mitochondrial LARS2 gene 
has shown an association with type 2 diabetes in work previously carried out by our 
group (6). The LARS2 gene encodes for the mitochondrial leucyl tRNA synthetase 
(EC 6.1.1.4), which catalyzes the aminoacylation of both mitochondrial leucyl 
tRNAs with leucine and is therefore essential for mitochondrial protein synthesis. 
By analyzing the coding region for the LARS2 gene we found an H324Q 
(rs71645922) variant, and demonstrated an association with type 2 diabetes 
susceptibility in a meta-analysis of four independent cohorts from the Netherlands 
and Denmark (OR = 1.40 (95% CI 1.12-1.76, P = 0.004, n = 7836) (6). 
In recent years the advent of genome-wide association studies (GWAS) and the 
accumulation of large data sets capable of detecting associations to levels of 
genome wide significance appropriate for such studies (p<5*10-8) has identified 
close to 20 loci impacting on type 2 diabetes susceptibility. However, low frequency 
variants such as H324Q are generally poorly captured by such studies. We set out 
therefore to re-evaluate the possible contribution of this LF variant to type 2 
diabetes susceptibility in appropriately sized samples. We also used a combination 
of publicly available (DIAGRAM consortium) and newly derived tagging SNP data 
to undertake the most comprehensive assessment of the LARS2 locus yet 
performed.  
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Materials and methods 
Study samples  
The first part of our study was aimed at the identification of common alleles 
associated with increased type 2 diabetes susceptibility using DIAGRAM 
consortium data and a tagging SNP approach. For this we genotyped several 
European samples.  
The first sample we included was from the Hoorn Study (here designated as NL1) 
(7). From this Dutch population based study from the city of Hoorn, in North-
Western Netherlands, we selected 519 normal glucose tolerant (NGT) subjects and 
480 type 2 diabetes subjects. Glucose tolerance was assessed using a fasting oral 
glucose tolerance test (OGTT), according to 1999 World Health Organization 
(WHO) criteria (8). This sample was used for the analysis of common variation in 
LARS2 with a tagging SNP approach. Variants in LARS2 identified from the 
DIAGRAM meta-analysis and the tagging SNP approach were then taken forward 
for replication in three Dutch samples, designated NL2, 3 and 4 respectively.  
The second sample from the Netherlands (designated NL2) included 1517 controls 
and 821 cases (9;10). The1517 controls were randomly selected from the New 
Hoorn Study (NHS), which is an ongoing, population based study from the city of 
Hoorn, which does not overlap with the original Hoorn Study (NL1). We included 
147 cases from the NHS and the remainder of the cases (n=674) were recruited 
from the diabetes clinics of the Leiden University Medical Centre (LUMC, Leiden) 
and from the Vrije Universiteit medical centre (VUmc, Amsterdam). All subjects in 
this replication sample were Dutch Caucasians and all NGT subjects underwent an 
OGTT according to WHO criteria(8). 
The third replication sample was ascertained from the Breda study (NL3) (11;12). 
This is a case control study from the city of Breda, in Southern Netherlands. The 
920 controls were from the Dutch blood bank and self reported a non-diabetic 
state. The 501 cases had type 2 diabetes based on WHO criteria (8).  
For the fourth replication sample we selected 5183 NGT subjects and 1222 type 2 
diabetes subjects from the population based ERGO study from the city of 
Rotterdam in the South-western region of the Netherlands (NL4) (13). 
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In total 8139 controls and 3024 type 2 diabetes cases were included in our 
replication study in the Netherlands.  
The second part of this study was focused on the follow up of 2 low frequency 
variants in LARS2 and for this we carried out replication in samples from the 
Netherlands (NL1-4) as well as samples from the UK (UK1,2), Denmark (DK1), 
Finland (FI1,2) and Sweden (SE1). 
We included one replication sample from Denmark (designated DK1) (14). This 
sample consists of 514 NGT controls which are randomly selected from public 
registers at the Steno Diabetes Center and the Research Centre for Prevention 
and Health, Copenhagen, Denmark. The 706 cases were recruited from the Steno 
Diabetes Center. NGT subjects underwent an OGTT according to WHO criteria (8).  
Two UK samples were included. The first (UK1) was the UKT2DGC (United 
Kingdom Type 2 Diabetes Genetics Consortium) case-control sample comprising 
4124 type 2 diabetes cases and 5126 controls ascertained in Tayside, Scotland. 
Details of the ascertainment scheme and recruitment criteria for this sample have 
been described elsewhere (15;16): the enlarged sample used here represents 
continuing recruitment to this resource under precisely the same criteria. The 
second sample (UK2) consists of 1853 type 2 diabetes cases ascertained as part 
of the BDA Warren 2 collection (Exeter, London, Oxford, Norwich and Newcastle) 
and 10220 control samples. The latter represent the full British 1958 Birth Cohort 
(n=7133) and The United Kingdom Blood Services Collection of Common Controls 
(UKBS) (n= 3087), a subset of which featured in the WTCCC genome wide 
association scan (both samples were collected throughout the UK) (15;16). 
Finally, we included samples from Finland and Sweden. One was a case-control 
sample from the Botnia region of Finland, here designated as FI1. This sample 
consisted of 353 controls and 402 cases. The second sample originated from 
Sweden (Skara and Malmö), here designated as the Swedish case-control study 
(SE1) and consisted of 468 controls and 480 cases (17;18). Furthermore, we 
included a set of trios originating from the Botnia region of Finland (FI2). This 
sample consisted of 211 probands (multiple diabetic sibs) and 370 parents. All 
study samples are summarized in table 1. 
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In total 25191 controls and 10800 type 2 diabetes cases were included for the 
follow up of the LF variants. 
All studies were approved by the appropriate medical ethical committees and were 
in accordance with the principles of the Declaration of Helsinki. All participants 
provided written, informed consent for this study. 
 
Common SNP selection 
Common SNPs (MAF >5%) in the LARS2 locus were selected for follow-up based 
on the data from the DIAGRAM meta-analysis (gene boundaries chr3: 
45373001…45698001) (22). SNPs with a P<0.05 were genotyped in the Dutch 
replication samples (NL1-4). Furthermore, tagging SNPs in LARS2 were selected 
for genotyping in the NL1 sample using the HapMap database and Tagger 
software (19;20) (selection criteria and SNPs shown in supplementary table S1). 
Table 1. Description of study samples. 
Subjects (%male) Mean Age (years)(SD) Mean BMI (Kg/m2)(SD)
 Study Controls cases controls cases controls cases 
NL1 519  (55) 
480  
(52) 
65  
(8) 
67  
(8) 
26.4  
(4.5) 
28.8  
(4.6) 
NL2 1517  (44) 
821  
(50) 
53  
(7) 
61  
(11) 
25.5  
(3.6) 
29.0 
(4.6) 
NL3 920  (61) 
501  
(46) 
48  
(13) 
71  
(10) n.a. 
27.8  
(4.1) 
NL4 5183  (41) 
1222  
(39) 
69  
(9) 
73  
(9) 
26.0  
(3.9) 
27.4  
(4.0) 
DK1 514  (46) 
706  
(48) 
57  
(10) 
59  
(10) 
25.9  
(3.8) 
29.3  
(5.1) 
UK1 5126 (51) 
4124  
(55) 
60 
(13) 
66  
(6) 
26.9  
(11.4) 
31.2 
(13.8) 
UK2 10220  (50) 
1853  
(61) 
42 
(7) 
57  
(9) 
27.2 
(6.4)a 
31.8  
(6.7) 
FI1 353  (53) 
402  
(55) 
60  
(10) 
61  
(10) 
26.1  
(3.6) 
28.7  
(4.5) 
FI2 370  (50)b 
211  
(47)c n.a 
40  
(9) 
28.5  
(5.5) n.a. 
SE1 468  (52) 
480  
(53) 
66  
(12) 
67  
(11) 
27.5  
(4.1) 
27.9  
(4.1) 
n.a. not available 
a. Based on the British 1958 Birth Cohort (7133) and Panel 2 of the United Kingdom Blood Services 
Collection of Common Controls (n=1643) 
b. parents 
c. probands 
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Genotyping and quality control 
SNPs selected for follow-up in our replication samples were genotyped using 
Taqman SNP genotyping assays (Applied Biosystems, Foster City, USA). Tagging 
SNPs were genotyped in the NL1 sample using the Sequenom platform 
(Sequenom, San Diego, USA). Assays showing overlapping clusters, success 
rates below 95% or not obeying Hardy Weinberg Equilibrium (HWE) (p<0.05) were 
excluded from analysis. Duplicate samples (~5%) showed complete concordance.  
 
Statistical analysis 
Differences in genotype distribution and allele frequencies were analyzed using a 
chi-squared test. ORs were calculated using an additive model, which was the best 
fit for the data. Homogeneity of ORs between the different samples was calculated 
with a Tarone’s test after which a common OR was calculated with a Mantel-
Haenszel test using a fixed effects model. Results from OGTT (only normal 
glucose tolerant subjects) were analyzed with univariate analysis of variance, using 
additive, recessive and dominant models and correction for age, BMI and gender 
as possible confounders. Association in the Botnia trios was assessed by the 
transmission disequilibrium test (TDT). All general statistics were calculated using 
SPSS 16.0 (SPSS Inc, Chicago, USA). For statistics involving the geographical 
distribution of the H324Q (rs71645922) variant in the UK population (described 
below) we used StatXact v 6.0 (Cytel software corps, Cambridge, MA, USA).  
Power calculations were performed using Quanto (21). From the DIAGRAM 
consortium meta-analysis of common variants we selected for replication all 
common SNPs with a p<0.05. At this alpha the DIAGRAM consortium meta-
analysis had at least 80% power to detect a variant with OR ≥1.20 (MAF >0.05) 
(22). Combined with our Dutch replication sample we had at least 80% power to 
replicate the association of a variant with an OR ≥1.09 at the observed MAFs of 
0.19 (rs952621) and 0.24 (rs17637703) respectively (alpha = 0.05) or OR ≥1.12 at 
alpha = 10-4). Power of the tagging SNP approach in NL1 was limited (80% power 
to detect a variant with an OR≥1.6 (alpha=0.05, MAF=0.05) or OR≥1.45 at the 
observed lowest MAF of 0.10) therefore we replicated in NL2-4 only our strongest 
signal from the NL1 sample (rs17637703, p = 0.07).  
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Whilst extensive GWAS have indicated that the effect sizes of common variants 
influencing type 2 diabetes risk are modest, the potential remains for low-frequency 
variants to have effects on type 2 diabetes risk that are more substantial which was 
corroborated by our previous observation regarding the H324Q variant (6). Power 
calculations at the start of the project demonstrated that we had at least 99% 
power to detect an effect size similar to our initial finding concerning H324Q 
(rs71645922) (OR 1.4) and at least 80% power to detect an OR of 1.13 (α=0.05) 
(6). From the DIAGRAM meta-analysis we used an alpha of 0.05 to select other LF 
SNPs for replication. At this alpha the power in DIAGRAM was 80% to detect 
association for variants with ORs ranging from 1.24 (MAF = 0.03) to 1.45 (MAF = 
0.01 and alpha = 0.05). For replication of the two low frequency variants (observed 
MAFs ~0.03(H324Q, rs71645922) and ~0.05 (rs9825041) respectively) we had in 
our complete replication sample at least 80% power to detect an OR ≥1.13 (25191 
controls and 10800 type 2 diabetes cases and alpha = 0.05).  
 
Results 
Common LARS2 variants in available DIAGRAM GWAS data  
We analyzed the data from the DIAGRAM GWAS meta-analysis (22) for the 
LARS2 gene (100% coverage (MAF > 5%), according to HapMap phase 2, April 
2007, CEU population) and observed 1 common SNP (rs952621, directly typed) 
showing weak evidence of association with type 2 diabetes (OR = 1.11 (1.02 – 
1.20), p = 0.01 for the T allele). This SNP was also captured in our complementary 
tagging SNP approach (NL1) and we found an OR of 1.13 (0.89 – 1.43), p = 0.33 
for the same allele. However, additional genotyping in the Dutch samples (NL2,4) 
and meta-analysis of all data resulted in a common OR of 1.05 (0.99 – 1.11), p = 
0.13 (n=19870). As there was no convincing evidence of association in our 
samples, this SNP was not analysed further. 
No other common SNP in LARS2 showed evidence for association with type 2 
diabetes in the GWAS data. The same was true of the tagging SNP analysis 
conducted in the NL1 sample (supplementary table s1). In the latter analysis, 
rs17637703 showed weak evidence of association (OR = 1.22 (95% C.I. 0.99 – 
1.50), p = 0.07) but this was not confirmed in the Dutch replication samples (the 
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common OR was 0.98 (0.91 – 1.06), p = 0.62 (n = 10087), in line with the 
DIAGRAM result for this SNP (OR 1.02 (0.94 – 1.10)). 
 
Low frequency variants in LARS2 
In addition to the common variants, the DIAGRAM meta-analysis also captured 
fourteen LF SNPs (0.01<MAF<0.05) within the LARS2 gene, ten of which are in 
high LD with each other (r2 > 0.95 according to HapMap, supplementary figure S1) 
and showed some evidence for association with type 2 diabetes (ORs 1.17 – 1.21; 
p 0.02 – 0.05). We selected rs9825041 (OR = 1.20 (1.03 – 1.39), p = 0.02) as a 
proxy for the group for genotyping in the replication samples but no association 
with type 2 diabetes was observed (table 2). Homogeneity of ORs was tested with 
a Tarone’s test (p = 0.67) and we calculated a common OR across all studies of 
1.03 (0.95 – 1.12), p = 0.45, (8959 cases, 23003 controls).  
 
Follow up of the H324Q (rs71645922) variant in LARS2 
Finally, we examined the association of the H324Q (rs71645922) variant with type 
2 diabetes in our replication samples from the Netherlands (NL2-4), UK (UK1, 2), 
Sweden (SE1) and Finland (FI1). This variant was not captured by the GWAS and 
was not captured by any of the SNPs mentioned above (r2 < 0.17). Subjects in the 
Dutch replication samples that were included in our original study of this variant 
were excluded from analysis (n = 914 from the NL4 study). The replication samples 
did not confirm our previously observed association. A meta-analysis of all 
available studies including our previous data from the Netherlands (NL1) and 
Denmark (DK1, 2) (6) resulted in an overall OR of 0.99 (0.90 – 1.08), p = 0.78, n = 
35715 subjects (10399 type 2 diabetes subjects, table 2). In addition, we did not 
observe a significant excess of transmission of the risk allele in the Botnia trios 
(FI2, transmitted / untransmitted = 18 / 14, OR 1.29 (0.64 – 2.59), p = 0.48).  
To investigate possible heterogeneity between the studies we performed several 
analyses. For age stratification we created, based on the age distribution in the 
Dutch samples the following age strata; ≤60 years, 61-70 years and >70 years. A 
decreased frequency of the risk allele was observed in type 2 diabetes subjects 
with increasing age in most but not all samples (data not shown, available on 
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request), but this did not reach statistical significance. Furthermore we looked at 
age at diagnosis of type 2 diabetes and allele frequencies in those with early onset 
diabetes (≤45 years) and those with an age at diagnosis above 45 years. Although 
the allele frequency was slightly higher in those with early onset diabetes this was 
not statistically significant nor was the age at diagnosis in carriers and non-carriers 
(all p > 0.05, data not shown). Stratification for gender and BMI (where data 
available) did not affect the outcome in the Dutch studies (NL1-NL4, data not 
shown) and was therefore not further investigated. 
H324Q (rs71645922) shows marked variation in MAF between the various 
European-descent samples examined (control MAF ranges from 1.9% to 4.8%). In 
the two large UK control samples, for example, there was a highly significant (p = 5 
· 10-7, using an exact implementation of the Cochran Armitage trend test) 
difference in allele frequencies between UK1 (recruited exclusively in Scotland) 
and UK2 (recruited throughout the UK) that made us consider the possibility that 
this variant was showing variation in allele frequency along the south-north cline 
previously described in the WTCCC study and others (16;23-26).To test this, we 
made use of information on the region of ascertainment available for the UK 1958 
Birth Cohort and UK Blood Service and analysed genotype frequencies based on 
subdivisions of the UK into 4 major regions, namely (1) Scotland, (2) Northern 
England(Yorkshire and the Humber, North East, North West), (3) UK Midlands 
(East Midlands, West Midlands, Wales, East of England) and (4) South of England 
(South East, Greater London, and South West). We found some evidence 
(supplementary figure S2) for a North - South gradient across the UK. (MAF 4.66 
%, 3.41%, 3.31%, and 3.28% respectively) with p = 0.038 calculated using the 
Jonckheere-Terpstra Test (StatXact v 6.0; Cytel software corporation, Cambridge, 
MA, USA). No such MAF gradient was observed in other European samples 
(supplementary figure S3) 
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Discussion 
We found no evidence of common SNPs in LARS2 being associated with type 2 
diabetes in our samples. We therefore conclude that it is unlikely that common 
SNPs in LARS2 are associated with type 2 diabetes susceptibility. 
Several low frequency SNPs, which are all in high LD with each other (r2 > 0.95) 
showed nominal evidence of association with type 2 diabetes in the DIAGRAM 
meta-analysis. However, we have been unable to confirm this association in our 
large replication samples from the Netherlands, Denmark and the UK (n = 31962) 
and therefore conclude that the nominal p-values observed in the GWAS are most 
likely consistent with statistical noise. 
The previously observed association of the H324Q (rs71645922) variant in LARS2 
with type 2 diabetes was not confirmed in our replication samples (table 2). Power 
Table 2. Genotyping results for rs9825041 and H324Q (rs71645922). 
rs9825041 H324Q (rs71645922) 
Study Controls
 
Cases OR 95% CI PAdd Controls Cases 
OR  
95% CI PAdd 
NL1 5.5  7.3  1.35  (0.92 – 1.98) 0.15 1.9 4.3 
2.26 
(1.10 – 4.66)a 0.04 
NL2 6.0  6.6  1.11 (0.85 – 1.44) 0.46 3.4 2.7 
0.78 
(0.49 – 1.25) 0.18 
NL3 5.7  6.8  1.21 (0.88 – 1.66) 0.25 3.3 3.0 
0.90 
(0.57 – 1.41) 0.74 
NL4 6.1  5.5  0.89 (0.74 – 1.08) 0.27 3.1 3.5 
1.11 
(0.84 – 1.47)a 0.47 
DK1 4.2 4.7 1.12  (0.75 – 1.68) 0.62 2.2 2.8 
1.24 
(0.74 – 2.09)a 0.44 
DK2 n.m.  n.m. n.m. n.m. 2.8 3.7 1.33 (0.97 – 1.82)a 0.08 
UK1 4.9 4.9 1.00 (0.87 – 1.14) 1.00 4.8 4.4 
0.91 
(0.79 – 1.05) 0.19 
UK2 4.8 5.1 1.05 (0.88 – 1.27) 0.57 3.6 3.4 
0.94 
(0.77 – 1.15) 0.59 
FI1 n.m. n.m. n.m. n.m. 4.2 4.9 1.18 (0.72 – 1.93) 0.51 
SE1 n.m. n.m. n.m. n.m. 4.5 4.2 0.94 (0.59 – 1.48) 0.79 
M-A   1.03
 
(0.95 – 1.12) 0.48
 
  
0.99 
(0.90 – 1.08) 0.82
 
DIAGRAMb   1.20  (1.03 – 1.39) 0.02   n.m. n.m. 
Minor allele frequencies are shown for cases and controls. 
n.m.: not measured 
M-A: meta-analysis 
a. Data taken from reference (6). Results from the NL4 study are partially from this previous research (n = 
914). 
b. Meta analysis of the DIAGRAM consortium GWAS, n = 10128 (4549 cases and 5579 controls) (22). 
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calculations at the start of the project demonstrated that we had at least 99% 
power to detect an effect size similar to our initial finding concerning H324Q 
(rs71645922) (OR 1.4) and at least 80% power to detect an OR of 1.13. Before 
excluding the previous association as false, we considered the possibility of 
heterogeneity but found no evidence that age, age at diagnosis, BMI and gender 
were responsible. Another possibility, raised by the evidence for variation in H324Q 
MAF across the UK is that the previous association in Dutch and Danish subjects 
reflected the effects of hidden population structure. It seems, however, unlikely that 
population stratification effects were responsible for the original reports of H324Q 
(rs71645922) associations as the cases and controls in that study were recruited 
from the same relatively narrow geographic regions within the Netherlands and 
Denmark (6). Also in our additional Dutch replication cohorts we could not detect a 
MAF gradient across the country. However, there are differences in MAF between 
different countries (supplementary Figure S2, S3). Migration patterns in the UK 
appear to reflect an increase in the MAF of H324Q (rs71645922) and therefore this 
may be a potential migration marker, however this needs to be demonstrated in 
other populations. Since stratification for BMI and gender did not affect our result, 
we can exclude that these variables confounded our observation. The reason for 
the discrepancy between our first and current study is likely to reflect chance. 
Three other low frequency non-synonymous SNPs are present in the LARS2 locus; 
K727N (rs36054230), E831D (rs9827689) and E868K (rs34965084). However, 
according to dbSNP and our own sequencing efforts (6) these SNPs are only 
identified in the African population and not polymorphic in the European population. 
Therefore, these additional non-synonymous variants were not analysed in this 
study. As our study does not include a thorough resequencing of the complete 
LARS2 locus we cannot fully exclude that other yet unknown LF variants are 
present and associated with type 2 diabetes. Results from the 1000 genomes 
project should facilitate a thorough investigation of LF SNPs in LARS2 in the future. 
In conclusion, our findings do not support the hypothesis that common variants in 
LARS2 are major type 2 diabetes susceptibility factors. We have also conducted 
one of the largest (up to 35715 subjects) replication studies for two low frequency 
variants for type 2 diabetes and also these data do not support a significant role as 
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type 2 diabetes susceptibility variants. We therefore conclude that currently known 
genetic variation in LARS2 does not play an important role in type 2 diabetes 
susceptibility. 
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Supplementary figure S1. LD plot of all known LF SNPs in the LARS2 locus. 
LD plot of all known LF SNPs in LARS2 (MAF ≤0.05; HAPMAP phase 2, CEU). r2 for each of the SNP 
pairs is given (black r2=1, shades of gray 0< r2<1 and white r2=0).  
The 14 LF SNPs directly genotyped in DIAGRAM are boxed. In the insert only the 14 LF SNPs included 
in the DIAGRAM scan are shown.  
rs9825041 was used as a proxy for the block and is shown in the box. 
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Supplementary figure S2. Geographic stratification in the UK for the H324Q (rs71645922) 
variant. 
 
The numbers represent minor allele frequencies of the H324Q (rs71645922) variant in each of the geographic 
regions. 
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Supplementary figure S3. Geographic stratification in other European samples. 
The numbers is the circles represent minor allele frequencies of H324Q (rs71645922) 
in each of the study samples. 
Chapter 2 
 
51 
 
Supplementary table S1. Overview of tagging SNPs, including results from the NL1 study. 
rs number Position Allele 1 
Allele 
2 
MAF 
controls 
MAF 
cases 
OR  
95% C.I. p-value 
rs854191 45409713 T C 0.19 0.16 0.86  0.68 – 1.08 0.22 
rs17637580 45411477 G A 0.33 0.35 1.08  0.89 – 1.30 0.45 
rs17077759 45411945 A C 0.23 0.20 0.86  0.69 – 1.07 0.17 
rs17637703 45415725 A G 0.22 0.25 1.22  0.99 – 1.50 0.07 
rs864391 45422021 G A 0.23 0.20 0.88  0.71 – 1.09 0.23 
rs6802884 45423962 T C 0.19 0.17 0.91 0.72 – 1.14 0.42 
rs17576051 45424984 A G 0.11 0.10 0.94  0.71 – 1.25 0.72 
rs3774696 45425473 A C 0.24 0.27 1.16  0.95 – 1.42 0.17 
rs9878643 45426336 G A n.a. n.a. n.a. n.a. 
rs6764923 45429693 A G 0.40 0.37 0.88  0.69 – 1.13 0.32 
rs17576289 45433737 A G 0.14 0.12 0.87  0.67 – 1.12 0.29 
rs4682783 45445335 A G n.a. n.a. n.a. n.a. 
rs4683113 45450337 A G 0.42 0.42 1.00  0.80 – 1.25 1.00 
rs9825692 45451366 G A 0.28 0.31 1.17  0.97 – 1.42 0.12 
rs952621 45451698 C T 0.18 0.20 1.13  0.89 – 1.43 0.33 
rs11926964 45464453 A T 0.18 0.16 0.89  0.70 – 1.13 0.34 
rs1877960 45471148 T C 0.29 0.28 0.95  0.73 – 1.24 0.74 
rs1949304 45475954 T C 0.28 0.28 0.97  0.74 – 1.26 0.84 
rs3774694 45481450 C T 0.31 0.32 1.02  0.84 – 1.23 0.89 
rs12487705 45492763 A G 0.36 0.38 1.12  0.93 – 1.34 0.26 
rs2128358 45524032 A G 0.13 0.13 1.04  0.80 – 1.34 0.79 
rs11706785 45546084 A G 0.43 0.42 0.95  0.75 – 1.19 0.64 
rs2118749 45547261 C T 0.28 0.30 1.09  0.84 – 1.42 0.54 
rs9825041 45502488 G A 0.06 0.07 1.35  0.92 – 1.98 0.15 
The LARS2 locus was also investigated using a tagging SNP approach in the NL1 sample.  
Common SNPs (MAF > 0.05), in LARS2 were identified using HAPMAP (gene boundaries set at 
45,405,079 - 45,565,332)[19].  
Tagging SNPs were selected using the Tagger option in Haploview (NCBI build 36, phase II, April 2007, 
population CEU, LOD threshold 3.0 and r2 > 0.8)[20].  
Allele 1 is the major and allele 2 is the minor allele.  
n.a.: not available.  
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Abstract 
Aims/hypothesis 
Mitochondria play an important role in many processes, like glucose metabolism, 
fatty acid oxidation and ATP synthesis. In this study we aimed to identify 
association of common polymorphisms in nuclear encoded genes involved in 
mitochondrial protein synthesis and biogenesis with type 2 diabetes using a two 
stage design.  
Methods  
In the first stage we analyzed 62 tagging SNPs in the Hoorn study (n = 999 
subjects), covering all common variation in 13 biological candidate genes. These 
13 candidate genes were selected from four clusters regarded essential for correct 
mitochondrial protein synthesis and biogenesis: aminoacyl tRNA synthetases, 
translation initiation factors, tRNA modifying enzymes and mitochondrial DNA 
transcription and replication. SNPs showing evidence for association with type 2 
diabetes were measured in second stage genotyping (n = 10164 subjects).  
Results 
After a meta-analysis only one SNP in SIRT4 (rs2522138) remained significant (p = 
0.01). Extending the second stage with samples from the Danish Steno Study (n = 
1220 subjects) resulted in a common OR of 0.92 (0.85 – 1.00), p = 0.06. Moreover, 
in a large meta-analysis of three genome wide association studies this SNP was 
also not associated with type 2 diabetes (p = 0.72).  
Conclusion 
In conclusion, we did not find evidence for association of common variants in 13 
nuclear encoded mitochondrial proteins with type 2 diabetes. 
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Introduction 
Mutations in genes involved in mitochondrial protein synthesis have been found to 
associate with a diabetic state. The 3243A>G mutation in the mitochondrial 
tRNA(Leu, UUR) gene, which impairs mitochondrial protein synthesis, is strongly 
diabetogenic as are some additional mutations in mtDNA encoded tRNA genes 
(1;2). Recently, we found that an H324Q variant in the nuclear encoded 
mitochondrial leucyl tRNA synthetase (LARS2) results in an increased type 2 
diabetes susceptibility (3). It seems that a change in the activity of mitochondrial 
protein synthesis makes the organism more vulnerable to develop glucose 
intolerance. 
A change in mitochondrial protein synthesis is expected to result in an unbalance 
in the stoichiometry of the proteins composing the respiratory chain. Some proteins 
of the respiratory chain are synthesized through the mitochondrial protein synthesis 
machinery, whereas the others are synthesized in the cytosol and imported into the 
mitochondrion. Impaired activity of the mitochondrial protein synthesis machinery is 
therefore expected to result in an unbalance between the nuclear DNA- and 
mitochondrial DNA-encoded proteins of the respiratory chain. A similar situation of 
an unbalance may arise when the rate of mitochondrial biogenesis is altered. 
In type 2 diabetes a reduced activity of the respiratory chain is seen, which is also 
present in first degree relatives (4;5). The biochemical basis of this phenomenon 
may arise through an unbalanced expression of the various proteins. Based on 
these considerations, we hypothesized that polymorphisms in genes involved in 
mitochondrial protein synthesis and mitochondrial biogenesis may alter the 
balanced expression of proteins of the respiratory chain. As a result these 
polymorphisms are expected to modify the risk for type 2 diabetes. It is estimated 
that the complete mitochondrial proteome consists of approximately 1500 proteins, 
which are mostly encoded by the nuclear genome (6). Common variations in genes 
encoded by the mitochondrial genome are not associated with the onset of type 2 
diabetes (7;8). Based on a literature study, we selected 13 candidate genes 
divided in several clusters. These candidates are all nuclear genes encoding for 
mitochondrial proteins.  
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Because of previous association of LARS2 with type 2 diabetes the first cluster 
consisted of the mitochondrial aminoacyl-tRNA synthetases DARS2, TARS2 and 
IARS2. DARS2 and TARS2 are located on a widely replicated type 2 diabetes 
linkage locus on chromosome 1q (9). Furthermore, variants in the tRNAIle gene 
were shown to be associated with metabolic disorders (10).  
The second cluster consisted of the two mitochondrial translation initiation factors, 
MTIF2 and MTIF3. These two genes are involved in initiation of the mitochondrial 
protein synthesis and dysfunction could lead to altered expression of mitochondrial 
proteins and subsequently to oxidative stress and late onset disease (11-13). We 
have selected them above other important translation factors, like TUFM, TSFM 
and GFM1, because mutations in the latter have already been associated with 
severe early onset disease (14).  
The third cluster consisted of MTO1, TRMU and GTPBP3, which all encode tRNA 
modifying enzymes. Variation in these genes could lead to dysfunctional enzymes 
and subsequently result in impaired tRNA modification and mitochondrial disease 
(15-17).  
In our fourth cluster we included TFAM and PPRC1, which are involved in 
transcription and replication of the mitochondrial genome. Previously, it has been 
shown that a low mitochondrial copy number is associated with type 2 diabetes, 
although this is not confirmed in all studies (18;19). TFAM is one of the main 
regulators of mitochondrial transcription and replication and thus of the 
mitochondrial copy number (20;21). PPRC1 is a PPARGC1A related gene and 
involved in mitochondrial biogenesis (22).  
In addition, we selected 3 genes, which did not fit in a specific cluster but may 
affect mitochondrial biogenesis and function. SIRT3 and SIRT4, which are Sir2 
homologues, are involved in mitochondrial function and insulin secretion (23;24). 
Moreover, SIRT3 has been associated with longevity (25). GPAM is the final 
candidate gene, which is involved in triacylglycerol and phospholipid synthesis. 
GPAM knock out mice show hyperinsulinemia and reduced glucose tolerance 
(26;27). Therefore, we hypothesized that defects in GPAM could lead to insulin 
resistance and subsequently type 2 diabetes.  
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Dysfunction of these 13 candidate genes potentially affects mitochondrial function 
and may therefore increase type 2 diabetes susceptibility. Therefore, the aim of the 
present study was to analyze the association of common variants in these gene 
loci with type 2 diabetes, using a tagging SNP approach. 
 
Materials and methods 
 
SNP selection 
Tagging SNPs were selected using the HapMap database (www.HAPMAP.org) 
and Tagger (28;29). The threshold for the minor allele frequency (MAF) was set at 
0.05. Using Tagger 62 SNPs were selected, which cover all common variation in 
the selected genes according to HapMap data (phase 2, April 2007 (Build 36), 
population CEU, r2 > 0.8). Aggressive tagging with 2- and 3-marker tests was used. 
This resulted in 4 multimarker tests. The remaining tests were all single marker 
tests. Gene boundaries include 5’ and 3’ UTR regions. Details about the SNP 
selection for the individual genes, including gene boundaries, are summarized in 
table 1.  
 
Genotyping and quality control 
A two stage design was used. For first stage genotyping the Sequenom platform 
(Sequenom, San Diego, USA) was used. First, the allelic discrimination plots were 
visually observed for good clustering. Assays with bad clustering were not further 
analyzed. SNPs with a success rate below 95% or not obeying Hardy Weinberg 
Equilibrium (HWE) (p < 0.01) were excluded from analysis. SNPs which did not fit 
in the Sequenom assay or failed quality control (QC) were genotyped with Taqman 
SNP genotyping assays (Applied Biosystems, Foster City, USA) and evaluated 
with the same QC guidelines. Duplicate samples (~5%) showed identical 
genotypes. SNPs showing evidence for association with type 2 diabetes (p < 0.05) 
were selected for second stage genotyping. Taqman SNP genotyping assays were 
used for this.
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Study cohorts 
The first stage genotyping was performed in the Hoorn study (30). This population 
based study consists of 519 normal glucose tolerant (NGT) subjects (aged 65 ± 8 
years, 55% male) and 480 type 2 diabetes subjects (aged 67 ± 8 years, 52% 
male). Glucose tolerance was tested using a fasting oral glucose tolerance test 
(OGTT), according to World Health Organization (WHO) criteria (31). 
For the second stage genotyping three cohorts from the Netherlands were pooled. 
The first cohort was the New Hoorn Study (NHS), which is an ongoing second non 
overlapping population based study in Hoorn (32). From this study we randomly 
selected 1517 NGT and 147 type 2 diabetes subjects. All subjects underwent an 
OGTT according to WHO criteria (31). In order to increase power we included 674 
subjects with type 2 diabetes from the diabetes clinics of the Leiden University 
Medical Center (LUMC, Leiden) and from the Vrije Universiteit medical center 
(VUmc, Amsterdam). All subjects were Dutch Caucasians. In total the NHS sample 
includes 1517 controls (aged 53 ± 7 years, 44% male) and 821 cases (aged 61 ± 
11 years, 50% male).  
Table 1. Gene boundaries and SNPs in the selected candidate genes. 
Gene Chr 
Gene boundaries for SNP 
selection 
SNPs  
(successful) 
% covered 
(MAF > 0.05) 
TARS2 1 148726544 - 148746371 4 (4) 100 
DARS2 1 172060581 - 172094305 2 (1) 28 
IARS2 1 218334078 - 218387999 6 (4) 81 
MTIF2 2 55317262 - 55349888 7 (7) 100 
MTO1 6 74228209 - 74267896 5 (5) 100 
TFAM 10 59815181 - 59825901 5 (5) 100 
PPRC1 10 103882777 - 103900078 3 (3) 100 
GPAM 10 113899611 - 113933507 6 (6) 100 
SIRT3 11 205031 – 226361 10 (10) 100 
SIRT4 12 119224546 - 119235427 3 (3) 100 
MTIF3 13 26907783 - 26922711 3 (3) 100 
GTPBP3 19 17309379 - 17314530 4 (4) 100 
TRMU 22 45109962 - 45131900 4 (3) 81 
Gene boundaries and coverage according to HapMap data. Gene boundaries according to 
genome build 36. 
The widest gene boundaries were used when more isoforms are known. 
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The second cohort was the Breda study (33;34). This case/control study consists of 
920 healthy controls (according to self report) from the Dutch blood bank (aged 48 
± 13 years, 61% male). The 501 cases (aged 71 ± 10 years, 46% male) are type 2 
diabetes patients according to WHO criteria (31).  
The third cohort was the ERGO study from Rotterdam (35). This population based 
study consists of 5183 NGT subjects (aged 69 ± 9 years, 41 % male) and 1222 (73 
± 9 years, 39 % male) type 2 diabetes patients.  
In total for the second stage genotyping we used 7620 controls and 2544 type 2 
diabetes cases. The characteristics of both stages are summarized in table 2 
(characteristics of the independent cohorts are summarized in supplementary table 
s1). For additional replication of our strongest signal we extended the second stage 
with samples from the Danish Steno study (36). This case/control study consisted 
of 514 NGT controls (aged 57 ± 10, 46% male) randomly selected from public 
registers at the Steno Diabetes Center and the Research Center for Prevention 
and Health. The 706 cases (aged 59 ± 10 years, 48% male) were recruited from 
the Steno Diabetes Center. 
Table 2. Descriptive statistics of the first and second stage. 
First stage Second stage  
controls cases controls cases 
Subjects  
(% male) 
519  
(55) 
480  
(52) 
7620  
(44) 
2544  
(45) 
Age - years  
(std. dev.) 
65  
(8) 
67  
(8) 
63  
(12) 
68  
(12) 
BMI - kg / m2  
(std. dev.) 
26  
(5) 
29  
(5) 
26  
(4) 
27  
(5) 
FPG - mmol / L  
(std. dev.) 
5.4  
(0.4) 
7.7  
(2.2) 
5.5  
(0.5)1 
8.3  
(2.5)1 
1) available for 2438 controls and 334 cases 
First stage consists of subjects from the Hoorn study (30). Second stage is a 
pooled sample of subjects original from the NHS, Breda studies and ERGO (33-
35).  
FPG = Fasting Plasma Glucose 
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Statistical analysis 
Differences in genotype distribution and allele frequency were analyzed using a 
chi-squared test. An additive model was the best fit for most of the SNPs. 
Rs1049432 (TFAM) and rs4917960 (PPRC1) might better fit a recessive model 
and were therefore also analyzed with this model. A common allelic OR covering 
both stages was calculated in a meta-analysis, using a Mantel-Haenszel test. 
Homogeneity of ORs between the different cohorts was tested using a Tarone’s 
test. Results from OGTT (only normal glucose tolerant subjects) were analyzed 
with univariate analysis of variance, using additive, dominant and recessive models 
and correction for age, BMI and gender as possible confounders. Power 
calculations were performed using Quanto (37). Power to detect modest effects in 
the first stage was limited (80% power to detect OR 1.45, MAF = 0.1). Therefore 
we did not correct for multiple testing but rather performed extensive replication of 
all signals from the first stage with p < 0.05. All statistics were calculated using 
SPSS 14.0 (SPSS Inc, Chicago, USA). 
 
Results 
Of the 62 SNPs tested in the first stage genotyping 58 SNPs passed QC 
guidelines. Of these SNPs we selected the top seven SNPs for second stage 
genotyping (p < 0.05). Data from genome wide association studies (GWAS), which 
came available after completion of our study resulted in the inclusion of two 
additional SNPs, rs4397793 in TFAM and rs2792751 in GPAM. Compared to our 
data both showed a similar effect in at least one of the publically available 
databases of GWAS (38;39). In total 9 SNPs were selected for genotyping in the 
second stage (table 3).  
We analyzed the second stage results for rs1049432 in TFAM and rs4917960 in 
PPRC1 first with a recessive model because that was the best fit for the first stage 
data (prec = 0.002 and prec = 0.07 resp). However, 2nd stage results showed no 
support for this model, therefore the additive model was used for further analyses. 
There was no evidence of heterogeneity of ORs between the independent cohorts, 
therefore we pooled all second stage data. A meta-analysis of both stages was 
performed in order to calculate a common OR for the 9 selected SNPs (table 3). 
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Only the G allele of rs2522138 in SIRT4 remained significant (p = 0.01), but this 
was mainly caused by stage 1 results. In order to confirm the observed association 
we expanded the second stage with the Danish Steno study resulting in a common 
odds ratio of 0.92 (0.85 – 1.00), p = 0.06.  
The C allele of rs4917960 in PPRC1 was borderline significant after the meta-
analysis (OR = 1.06 (1.00 – 1.13) p=0.06). This association was nominal and 
mainly caused by stage 1 data. The ORs in all independent cohorts are shown in 
supplementary table 2. Correction for age, gender and BMI (when available) did 
not influence the results.  
Finally, we analyzed OGTT data for association of the selected genes with 
differences in clinical variables like glucose and insulin. Furthermore, association 
with BMI was assessed when the data were available. No differences were 
observed using different models (data not shown). 
Table 3. Results of first and second phase genotyping. 
MAF 1 1st Stage 2nd Stage Meta-analysis 
Rs-number Gene 
controls cases OR 95% CI PAdd 
OR 
95% CI PAdd 
OR 
95% CI PAdd 
rs1937 2 TFAM 0.14 0.09 0.66 0.50-0.88 0.005 
1.00 
0.86-1.17 0.97 
0.91 
0.79-1.04 0.17 
rs4397793 TFAM 0.41 0.37 0.86 0.72-1.03 0.10 
1.04 
0.97-1.11 0.25 
1.02 
0.95-1.08 0.62 
rs1049432 TFAM 0.19 0.14 0.77 0.61-0.97 0.03 
1.00 
0.91-1.09 0.95 
0.97 
0.89-1.05 0.39 
rs4917960 PPRC1 0.38 0.42 1.12 1.00-1.43 0.05 
1.05 
0.98-1.12 0.21 
1.06 
1.00-1.13 0.06 
rs17129583 GPAM 0.12 0.16 1.32 1.02-1.70 0.04 
0.92 
0.84-1.02 0.12 
0.97 
0.88-1.06 0.50 
rs2792751 GPAM 0.26 0.24 0.87 0.71-1.06 0.18 
1.01 
0.94-1.09 0.81 
0.99 
0.93-1.06 0.82 
rs535716 SIRT3 0.24 0.19 0.78 0.63-0.96 0.02 
1.05 
0.97-1.13 0.25 
1.01 
0.94-1.09 0.78 
rs2522138 3 SIRT4 0.18 0.13 0.69 0.54-0.88 0.003 
0.93 
0.85-1.02 0.13 
0.92 
0.85-1.00 0.06 
rs17085633 MTIF3 0.44 0.50 1.25 1.05-1.50 0.01 
1.02 
0.97-1.09 0.55 
1.05 
0.98-1.11 0.15 
1) MAF in first stage genotyping (Hoorn study). 
2) Second stage genotyping only in NHS and Breda study (n = 3759). 
3) Meta-analysis includes Steno study. 
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After completion of our study, a meta-analysis of three type 2 diabetes GWAS 
appeared (40). The coverage of common variation in the 13 selected genes in the 
GWAS was between 80 and 100% except GTPBP3, which was covered for 50%. 
We compared our results with the GWAS data, using the OR-based analysis (table 
4). The G allele of rs2522138 in SIRT4 was not associated with type 2 diabetes 
susceptibility in the GWAS data (OR = 1.02 (0.93 - 1.11), p = 0.72). The C allele of 
rs4917960 in PPRC1 showed an OR of 1.04 (0.97 – 1.12), p = 0.23) in the GWAS, 
which is in the same direction as observed in our study (OR = 1.06 (1.00 – 1.13), p 
= 0.06). Two SNPs located in IARS2 (the C alleles of rs17007135 and rs2289191) 
showed evidence of nominal association in the GWAS meta-analysis (p = 6 * 10 -4 
and p = 0.003, respectively.). Unfortunately, the assays for these two SNPs failed 
in our study. None of the other SNPs in our 13 genes showed evidence of 
association in the type 2 diabetes GWAS meta-analysis. 
Table 4. Comparison DIAGRAM meta-analysis and our replication SNPs 
Meta-analysis GWAS Meta-analysis of our study Rs 
number Gene OR 95% CI p-value 
OR 
95% CI p-value 
rs1937 TFAM 1.02 0.91 - 1.14 0.76 
0.91 
0.79 – 1.04 0.17 
rs4397793 TFAM 1.03 0.96 - 1.09 0.43 
1.02 
0.95 – 1.08 0.62 
rs1049432 TFAM 1.02 0.94 - 1.12 0.69 
0.97 
0.89 – 1.05 0.39 
rs4917960 PPRC1 1.04 0.97 - 1.12 0.23 
1.06 
1.00 – 1.13 0.06 
rs17129583 GPAM 1.00 0.92 – 1.09 0.99 
0.97 
0.88 – 1.06 0.50 
rs2792751 GPAM 1.04 0.98 - 1.11 0.22 
0.99 
0.93 - 1.06 0.82 
rs535716 SIRT3 1.03 0.96 - 1.11 0.42 
1.01 
0.94 – 1.09 0.78 
rs2522138 SIRT4 1.02 0.93 - 1.11 0.72 
0.92 
0.85 – 1.00 0.06 
rs17085633 MTIF3 1.00 0.94 - 1.06 0.89 
1.05 
0.98 – 1.11 0.15 
T2D: type 2 diabetes 
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Discussion 
We analyzed 58 tagging SNPs in 13 genes involved in mitochondrial function for 
association with type 2 diabetes susceptibility using a two stage design. After meta-
analysis of the data of both stages only rs2522138 in SIRT4 remained borderline 
significant. However, after extension of the second stage with samples from the 
Steno study, this association did not remain significant.  
For several gene variants measured in our study, there is substantial heterogeneity 
of ORs between the first and second stage, but not within each stage (Table 3 and 
supplementary table s2). Heterogeneity between the independent cohorts might be 
caused by the differences in the age, gender or selection criteria used and might 
obscure true association (supplementary table s1). However, we were unable to 
identify the reasons for this heterogeneity in our study. Differences in LD between 
the measured and causal SNP are also an unlikely cause, because the study 
subjects in our cohorts are from similar ancestry (41). In the context of testing 
multiple SNPs, our nominal significant results in SIRT4 and PPRC1 should be 
interpreted as consistent with statistical noise.  
One of the limitations of our study is that it is statistically underpowered to detect 
SNPs with a very small impact or low allele frequency. Although power in the first 
stage alone was low, we had at least a power of 80% at an observed minor allele 
frequency ≥ 0.13 to detect ORs comparable to those recently reported in GWAS 
(1.12 – 1.37) when first and second stage are combined (40). Our negative results 
for these 13 genes are confirmed by the DIAGRAM GWAS meta-analysis, which 
has a much higher power to detect also more modest effects (38-40;42). Taken 
together, we can exclude that common variants in the selected genes have a major 
impact on type 2 diabetes susceptibility. Rare variants are not covered by our 
approach so we cannot exclude a role for such variants. Deep sequencing and 
analysis of novel rare variants in large well phenotyped cohorts should provide 
more insight into these important issues.  
Other nuclear encoded mitochondrial genes are also not among the top hits of 
reported type 2 diabetes GWAS (38-40;42;43). Nevertheless, previous studies 
suggested that they may be involved in type 2 diabetes susceptibility (3;44-47). 
Further combined and detailed analysis of the available GWAS datasets and 
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analysis of copy number and so-called low frequency intermediate-penetrance 
variants are necessary to fully explore the role of nuclear encoded mitochondrial 
genes in the pathogenesis of type 2 diabetes.  
In conclusion, we were unable to detect association of common SNPs in 13 nuclear 
encoded mitochondrial candidate genes with type 2 diabetes or related continuous 
traits. 
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Supplementary table S1. Descriptive statistics of all individual cohorts. 
Hoorn Study NHS Breda Study ERGO Study Steno Study  
controls cases controls cases controls cases controls cases controls cases 
Subjects 
(% male) 
519 
(55) 
480 
(52) 
1517 
(44) 
821 
(50) 
920 
(61) 
501 
(46) 
5183 
(41) 
1222 
(39) 
514 
(46) 
706 
(48) 
Age  
(std. dev.) 
65  
(8) 
67  
(8) 
53  
(7) 
61  
(11) 
48  
(13) 
71  
(10) 
69  
(9) 
73  
(9) 
57  
(10) 
59  
(10) 
BMI  
(std. dev.) 
26  
(5) 
29  
(5) 
26  
(4) 1 
29  
(5)1 n.a. 
28  
(4) 
26  
(4) 
27  
(4) n.a. n.a. 
FPG 
(std. dev.) 
5.4 
(0.4) 
7.7 
(2.2) 
5.3 
(0.4)2 
7.6 
(2.1)2 n.a. n.a. 
5.7 
(0.6)3 
8.7 
(2.6)3 n.a. n.a. 
1) Only available for NHS subjects selected from the ongoing study, not from diabetic subjects from the LUMC and 
VUmc diabetes clinics (n=1664). 
2) 1517 controls and 147 cases 
3) 920 controls 187 cases 
n.a. = not available 
FPG = Fasting Plasma Glucose 
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 Supplementary table S2. Results of replicated SNPs for every independent cohort 
1st stage 2nd stage 
Hoorn Study NHS Breda Study ERGO Study Steno Study Rs 
number OR 
95% CI PAdd 
OR 
95% CI PAdd 
OR 
95% CI PAdd 
OR 
95% CI PAdd 
OR 
95% CI PAdd 
rs1937 0.66 0.50-0.88 0.005 
1.08 
0.88-1.33 0.46 
0.89 
0.70-1.13 0.37 n.a. n.a. n.a. n.a. 
rs4397793 0.86 0.72-1.03 0.10 
1.10 
0.95-1.28 0.20 
1.00 
0.85-1.17 1.00 
1.06 
0.97-1.16 0.22 n.a. n.a. 
rs1049432 0.77 0.61-0.97 0.03 
1.11 
0.91-1.35 0.29 
0.93 
0.74-1.17 0.56 
0.99 
0.88-1.12 0.90 n.a. n.a. 
rs4917960 1.12 1.00-1.43 0.05 
1.09 
0.94-1.26 0.28 
1.00 
0.86-1.18 0.97 
1.03 
0.94-1.13 0.51 n.a. n.a. 
rs17129583 1.32 1.02-1.70 0.04 
0.75 
0.60-0.93 0.01 
1.09 
0.88-1.36 0.46 
0.90 
0.79-1.04 0.15 n.a. n.a. 
rs2792751 0.87 0.71-1.06 0.18 
1.08 
0.92-1.27 0.35 
0.94 
0.79-1.12 0.50 
1.01 
0.91-1.11 0.92 n.a. n.a. 
rs535716 0.78 0.63-0.96 0.02 
1.05 
0.88-1.25 0.59 
0.97 
0.81-1.16 0.78 
1.06 
0.96-1.18 0.27 n.a. n.a. 
rs2522138 0.69 0.54-0.88 0.003 
0.98 
0.82-1.18 0.89 
0.84 
0.67-1.07 0.15 
0.98 
0.86-1.10 0.71 
1.13 
0.91-1.42 0.27 
rs17085633 1.25 1.05-1.50 0.01 
1.10 
0.95-1.28 0.21 
0.97 
0.83-1.14 0.72 
0.99 
0.91-1.09 0.91 n.a. n.a. 
n.a. = not available 
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Abstract 
Aims/hypothesis  
It has been shown that mitochondrial DNA (mtDNA) content is associated with type 
2 diabetes (T2D) and related traits. However, empirical data, often based on small 
samples, did not confirm this observation in all studies. Therefore, the role of 
mtDNA content in T2D remains elusive. In this study we assessed the heritability of 
mtDNA content in buccal cells and analyzed the association of mtDNA content in 
blood with prevalent and incident T2D.  
Methods  
Mitochondrial DNA content from cells from buccal and blood samples were 
assessed using a real time PCR based assay. Heritability of mtDNA content was 
estimated in 391 twins from The Netherlands Twin Register. The association with 
prevalent T2D was tested in a case / control study from the Netherlands (n=329). 
Incident T2D was analyzed using prospective samples from Finland (n=444) and 
the Netherlands (n=238). 
Results  
A heritability of mtDNA content of 35% (19%-48%) was estimated in the twin 
families. We did not observe evidence of an association between mtDNA content 
and prevalent or incident T2D and related traits. Furthermore, we observed a 
decline in mtDNA content with increasing age, which was male specific (p=0.001). 
Conclusion  
In this study we show that mtDNA content has a heritability of 35% in Dutch Twins. 
There is no association between mtDNA content in blood and prevalent or incident 
T2D and related traits in our study samples.
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Introduction 
Mitochondria contribute to multiple cellular processes such as ATP synthesis, beta-
oxidation of fatty acids and apoptosis. They have their own circular genome, of 
approximately 16kb which exists in multiple copies per mitochondrion. 
Mitochondrial DNA (mtDNA) encodes for 2 rRNA’s, all mitochondrial tRNA’s and 13 
subunits of the respiratory chain. These 13 subunits are synthesized by the 
mitochondrial protein synthesis machinery inside the mitochondrial matrix. Since 
the complete pool of mitochondrial proteins consists of approximately 1500 
proteins, only a fraction of them is encoded and synthesized inside the 
mitochondrion. Quantities of mtDNA, the so-called mtDNA content, vary between 
individuals and tissues within an individual. In muscle dynamic adaptation is 
observed in relation to physical exercise (1;2). Mutations in the human POLG gene 
and knock down of Tfam in mouse models, two of the most important regulators of 
mtDNA content, result in mtDNA depletion, showing that nuclear factors are 
involved in the regulation of mtDNA content (3;4). Furthermore, it has previously 
been shown in humans that the mtDNA content in blood cells is partially heritable 
(5;6). In this study we readdress the heritability of mtDNA content using buccal 
swabs from mono- and dizygotic twins and their siblings.  
Evidence is accumulating that mtDNA content is associated with type 2 diabetes. 
However, there is debate about whether mitochondrial dysfunction is primary or 
secondary to type 2 diabetes. HIV infected patients treated with Highly Active Anti 
Retroviral Therapy (HAART) containing nucleoside analogues, show a 30-50% 
decreased mtDNA content, redistribution of body fat, insulin resistance and an 
increased risk for development of type 2 diabetes, favouring the hypothesis that 
mitochondrial dysfunction is a cause rather than a consequence of development of 
type 2 diabetes (7-9).  
It has been shown that low mtDNA content precedes type 2 diabetes (10). 
However, in a sample of 141 non-diabetic, adult offspring who had one parent with 
T2D, no difference in mtDNA content in blood was observed compared to controls 
(11). Other studies showed evidence that mtDNA content is associated with the 
pattern of triglyceride storage, insulin secretion, insulin sensitivity and glucose 
Type 2 diabetes and mitochondrial DNA content 
 
76 
metabolism (12-15). Furthermore, mtDNA content is decreased in Goto-Kakizaki 
rat, which is a genetic model for type 2 diabetes (16).  
Since the association of mtDNA content with type 2 diabetes is not confirmed in all 
studies the role of mtDNA content in the onset of type 2 diabetes remains not fully 
understood. The aim of the current study was to elucidate this important issue. We 
assessed the heritability of mtDNA content in participants from the Netherlands 
Twin Register while taking into consideration several life style variables. Next, we 
assessed the association of mtDNA content with prevalent and incident cases of 
type 2 diabetes in a Dutch case-control study and in selected samples from two 
prospective studies form Finland and The Netherlands.  
 
Materials and methods 
 
Sample selection 
 
Heritability  
For estimation of the heritability participants were recruited from the Netherlands 
Twin Register (17;18). The sample consisted of 391 twins and 12 of their siblings 
from 212 families as part of a study on depression and anxiety (19) and smoking 
behavior (20). DNA was extracted from buccal cells. Assessment of zygosity was 
based on DNA polymorphisms. There were 183 complete twin pairs (38 
monozygotic male (MZM), 23 dizygotic male (DZM), 60 monozygotic female (MZF), 
45 dizygotic female (DZF) and 17 DZ pairs of opposite sex) and 25 incomplete 
pairs (5 MZM, 3 DZM, 12 MZF and 5 DZF). The sibling group consisted of 5 males 
and 7 females.  
Information on BMI, smoking, and exercise was obtained from longitudinal surveys 
and from data collected at the time of DNA sampling. 
 
Case / control study of prevalent type 2 diabetes 
For the case control study we selected 175 normal glucose tolerant (NGT) 
Caucasian participants from the Dutch New Hoorn Study (NHS). 154 prevalent 
type 2 diabetes patients from NHS and the Diabetes Care System West-Friesland 
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(DCS) were matched for age (21-23). NHS is a population based study from the 
city of Hoorn, the Netherlands, which aims to examine potential determinants for 
glucose intolerance and related disorders. Glucose tolerance was assessed by oral 
glucose tolerance test (OGTT) following WHO ’99 criteria (24). DCS aims to 
improve diabetes care by coordinating the diabetes care involving all caregivers 
and providing education of patients in order to improve patient empowerment. 
Patients are referred to the DCS by their physicians and are from the same 
geographical region as the NHS. DNA was extracted from whole blood. 
 
Prospective study of incident type 2 diabetes 
In order to prospectively analyze the association between mtDNA content and 
incident cases of type 2 diabetes we selected samples from 2 prospective studies. 
The first was the Botnia study, here designated prospective 1, which aims at the 
identification of genes increasing susceptibility to type 2 diabetes (25). This family 
study includes 2770 participants, which were healthy at baseline, originating from 
the Botnia region in Finland. Glucose tolerance at baseline and after follow up was 
tested using OGTT following WHO ’99 criteria (24). DNA was extracted from whole 
blood, drawn at baseline. DNA from 133 participants who converted to type 2 
diabetes (converters) was available. 311 non-converters were matched based on 
age, and BMI at baseline and gender. We allowed the inclusion of impaired 
glucose tolerant (IGT) and impaired fasting glucose (IFG) participants since these 
covered a large proportion of the converter group. The converter group included 55 
NGT, 37 IGT, 20 IFG and 24 IGT+IFG participants at baseline. The non-converter 
group included 245 NGT, 45 IGT, 26 IFG and 15 IGT+IFG participants at baseline. 
Family-history (first degree relatives) of type 2 diabetes was present in 83.8% of 
the converter and 67.2% of the non-converter group.  
The second prospective study was the Dutch Rotterdam study (n = 7983), here 
designated prospective 2, which is a population based study aiming to investigate 
determinants of disease occurrence and progression in the elderly (26). DNA was 
extracted from buffy coat, obtained from blood drawn at baseline. Diabetic state at 
baseline was assessed using a random glucose tolerance test, which was shown 
to have a good correlation with OGTT (27). Glucose tolerance after follow up was 
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assessed using OGTT following WHO ’99 criteria (24). From this study 113 
converters were available. We matched 125 non-converters based on age and BMI 
at baseline and gender. Entry of IGT participants at base line was allowed (n = 20 
in the converter group and n = 1 in the non-converter group).  
All studies were approved by the appropriate medical ethical committees and were 
in accordance with the principles of the Declaration of Helsinki. Study samples are 
summarized in table 1.  
Measurement of mitochondrial DNA content  
Mitochondrial DNA content was assessed using a modification of the quantitative 
real time PCR based method we described previously (28). In short, the relative 
amount of mtDNA was quantified by comparison with a nuclear target, which was 
the beta-globin gene (HBB). A fragment of mtDNA was amplified between 
nucleotide position 3780 and 3842, which is located in MT-ND1 on the heavy 
strand transcript (primer sequences available on request). Quantitative real time 
PCR was performed using the Applied Biosystems 7900HT (Applied Biosystems, 
Applied Biosystems, Foster City, USA). Absolute QPCR SYBR Green ROX mix 
was used (Thermo Fisher Scientific Inc., Waltham, MA, USA). For quantification 
reference curves were used, which were serial dilutions of a standard DNA. A ratio 
between mtDNA and HBB was calculated (mtDNA / HBB), which is here used as 
the mtDNA content. Each sample was measured at least in triplicate and mean 
values were calculated. Specificity of amplification was tested by dissociation 
curves and water controls. Approximately 50% of samples were repeated and 
showed a high concordance in all study samples with initial results (r2 ≥ 0.8). 
 
Table 1. Characteristics of study samples 
Dutch case/control Prospective 1 Prospective 2 
 
Twins / 
Heritability Cases Controls Converters Non- 
converters Converters 
Non- 
converters 
N  
(%male) 
403 
(38) 
154 
(49) 
175  
(49) 
133  
(50) 
311  
(45) 
113  
(60) 
125  
(50) 
Age  
(stdev) 
38.7 
(11.7) 
55 
(4) 
52  
(6) 
53  
(12) 
53  
(9) 
66  
(6) 
65  
(5) 
BMI  
(stdev) 
24.0  
(3.7) 
31.1 
(5.8) 
25.8  
(3.5) 
28.8  
(4.3) 
26.8  
(2.9) 
28.5  
(3.5) 
28.4  
(2.7) 
Mean with SD are shown. 
n.a.: not available 
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Mitochondrial DNA content is assessed in several tissues (buccal cells, whole 
blood and buffy coats). It is known that DNA extraction from these different 
samples can result in variance in mtDNA content. Therefore, differences in mtDNA 
content between the independent study samples is observed (29;30). 
 
Statistical analysis 
 
Heritability study 
Twin studies make use of the genetic relatedness of twins and their family 
members. MZ twins are genetically identical while DZ twins share on average 50% 
of their segregating genes, like other siblings (31). Twin studies compare the 
correlation of a phenotype, such as mtDNA content, within MZ twin pairs with the 
resemblance within DZ twin and sibling pairs. If the correlation in MZ twins is about 
twice as large as the correlation in DZ twins, familial resemblance is explained by 
additive genetic effects (A). When the DZ correlation is more than half the MZ 
correlation, there is evidence for environmental (C) effects shared by twins and 
siblings from the same family. Differences within MZ twin pairs are due to unique 
environmental influences (E), which also include measurement error . The 
observed variance thus can be decomposed into variance components A, C and E 
(32). 
Statistical analyses were performed using structural equation modeling as 
implemented in the software package Mx (33). The raw data full information 
maximum likelihood approach in Mx was used to fit different models to the data, for 
example ACE and AE models. Testing of sub models was done by means of 
likelihood-ratio tests, by subtracting the negative log likelihood (-2LL) for the more 
restricted model (e.g. AE) from the -2LL for the more general model (e.g. ACE). 
This yields a statistic that is distributed as χ² with degrees of freedom (df) equal to 
the difference in the number of parameters in the two models. We first fitted a 
saturated model to the data in which means, variances, and correlations were 
estimated as well fixed effects of age, sex, BMI and physical activity on mtDNA 
content. 
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Case / control study of prevalent type 2 diabetes 
The association of mtDNA content with prevalent type 2 diabetes in the case 
control study was analyzed with logistic regression with adjustment for age, gender 
and BMI. Mitochondrial DNA content in each cohort was adjusted for age, gender 
and BMI with general linear models. Continuous traits where analyzed with linear 
regression with adjustment for age, BMI and gender (were appropriate) only in 
NGT participants. SPSS (SPSS Inc, Chicago, USA) was used for these statistical 
analyses. 
 
Prospective study of incident type 2 diabetes 
Since the prospective 1 sample (Botnia study) is a family based study, we adjusted 
for family relation. In order to do so, we made use of general estimating equations 
with logistic regression, which takes into account family relatedness when 
calculating the standard errors. Conversion to type 2 diabetes was adjusted for 
age, BMI and glucose tolerance at baseline and gender and family history of 
diabetes. Estimated average mtDNA content was calculated with generalized 
estimated equations with linear regression, with similar adjustments as mentioned 
above.  
The prospective 2 sample (Rotterdam study) is a sample of the population of 
Rotterdam, The Netherlands. We used standard logistic regression with adjustment 
for age, BMI and glucose tolerance at baseline and gender. Estimated average 
mtDNA content and continuous traits were analyzed with a general linear model, 
using adjustment for age, BMI and glucose tolerance at baseline and gender. 
 
Power calculation 
Prior to the study, power calculations were performed, using Lenth’s power and 
sample-size calculator (http://www.stat.uiowa.edu/~rlenth/Power/index.html 
website accessed on May 20 2008). We assumed a population standard deviation 
of 30%. For the association with prevalent or incident type 2 diabetes a sample 
size of 160 cases and controls is needed for 80% power to detect a difference of at 
least 10% (alpha = 0.05).  
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Results 
 
Heritability 
Regression of gender, age, exercise and BMI on mtDNA content indicated that mean 
mtDNA content was lower in subjects who do not exercise, in women, who are older and 
who have a higher BMI. These four covariates thus explain a significant part (4%) of the 
variance in mtDNA content. Genetic modeling with these covariates yielded twin 
correlations of 0.34 for MZ and 0.19 for DZ/sib pairs. The corrected mean mtDNA was 
1.28 with an SD of 0.02. Comparing an ACE model (-2LL = 1996.76) with an AE model (-
2LL = 1996.77) indicated that C (shared environmental effects) could be dropped without 
loss of fit. Finally, fitting a model (E Model) that specified no familial (genetic) variance 
showed a significantly worse fit (-2LL = 2014.24, χ² of 17.49 with 1 df when compared to 
AE model; p = 2·10-5), showing that genetic factors do have a significant effect on 
mitochondrial content. Heritability under the best model (AE) was estimated at 35% (CI 
19%-48%). 
 
Prevalent type 2 diabetes and mitochondrial DNA content 
Mitochondrial DNA content was assessed in a case control study ascertained from 
the Dutch NHS and DCS, originating from the same geographic location. Estimated 
mean mtDNA content in prevalent cases of type 2 diabetes and controls was 0.30 
(0.28 – 0.31) and 0.29 (0.28 – 0.30) respectively, p = 0.51 (table 2). Also after 
Table 2. Association of mitochondrial DNA content with (future) type 2 diabetes 
mtDNA content Study Case Control p-value 
Case / Controla 0.30 (0.28 – 0.31) 
0.29 
(0.28 – 0.30) 0.51 
Prospective 1b 0.38 (0.36 – 0.40) 
0.40 
(0.39 – 0.42) 0.08 
Prospective 2c 0.55 (0.50 – 0.59) 
0.51 
(0.46 – 0.56) 0.18 
Estimated mitochondrial DNA content is shown as the ratio between nDNA and mtDNA 
with 95% CI and p-values. 
a. Adjusted for age, BMI and gender using general linear model. 
b. Adjusted for age, BMI, gender, family history of type 2 diabetes, pedigree clustering 
and glucose tolerance at baseline using generalized estimated equations. 
c. Adjusted for age, BMI, gender and glucose tolerance at baseline using general linear 
model. 
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logistic regression with adjustment for possible confounders (BMI, age and gender) 
we could not detect an effect on type 2 diabetes susceptibility (p = 0.56). 
Furthermore, we could not find any evidence for a correlation between mtDNA 
content and other relevant variables (supplementary table S1 and S2).  
 
Incident type 2 diabetes and mitochondrial DNA content 
Mitochondrial DNA content was first assessed in the prospective 1 sample. 
Estimated mean mtDNA content in converters and non-converters was 0.38 (0.36 – 
0.40) and 0.40 (0.39 – 0.42) respectively, p = 0.08 (table 2). Using logistic 
regression with adjustment for possible confounders (age, gender, BMI, glucose 
tolerance at baseline and family clustering) we also observed a weak regression 
towards decreased mtDNA content with increased type 2 diabetes risk, but this did 
not reach statistical significance (p = 0.10). No associations between mtDNA 
content and OGTT derived variables were observed.  
Next, mtDNA content was assessed in the prospective 2 sample. Estimated mean 
mtDNA content in converters and non-converters was 0.55 (0.50 – 0.59) and 0.51 
(0.46 – 0.56) respectively, p = 0.18 (table 2). Logistic regression with adjustment 
for possible confounders gave a similar result (p = 0.17).  
 
All studies showed a trend towards decreasing mtDNA content with increasing age 
(supplementary table S1). However, for most studies, this did not reach statistical 
significance. Therefore, we pooled all data in order to increase power and repeated 
the analysis. Mitochondrial DNA content of each independent study was 
normalized using the average mtDNA content to make the data comparable. To 
avoid heterogeneity, we excluded the twin data for this analysis, since this was the 
only study for which DNA was extracted from buccal swabs. Using generalized 
estimating equations with correction for family relatedness and study sample, we 
observed a statistical significant decrease in mtDNA content with increasing age  
(B = -0.003 (-0.005 to -0.0007), p = 0.009). Correction for BMI did not influence the 
data. However, the association seems to be gender specific. No effect of age on 
mtDNA content was observed in females (p = 0.53), while a strong association was 
observed in males (B = -0.005 / year (-0.008 to -0.002), p = 0.001). Furthermore, 
Chapter 4 
 
83 
BMI showed a trend towards association with mtDNA content (B = -0.81 (-1.65 to 
0.03), p = 0.06) in the pooled data set. After correction for age and gender, the 
association is borderline significant (B = -0.92 (-1.78 to -0.07), p = 0.04). Exercise 
data for the pooled sample was only available from the case / control and 
prospective 1 sample and did not influence this association (data not shown). We 
also observed different mtDNA content between males and females. Females 
showed a ~5% higher mtDNA content (p = 0.007). Correction for age and BMI 
revealed an estimated mtDNA content in males vs. females of 0.96 (0.93 to 0.98) 
and 1.01 (0.98 to 1.04) respectively (p = 0.007, supplementary table S2). The 
pooled sample was not corrected for exercise, since assessment of exercise was 
performed with different questionnaires.  
 
Discussion 
Heritability 
In this study we showed that mtDNA content has a heritability of 35% (CI: 19% – 
48%) in buccal cells. This partially confirms results from other groups who analyzed 
mtDNA content in blood and reported heritability between 33% and 65% (5;6). 
However, the reported heritability of 65% is higher than our finding. This might be 
caused by a different ethnicity of participants or different types of tissue used.  
In our study mtDNA content in buccal cells is not affected by smoking behaviour, 
so this could not bias our results. However, two other studies did show modest 
effects of smoking on mtDNA content in buccal cells and whole blood (6;34).  
 
Prevalent type 2 diabetes and mitochondrial DNA content 
Inconsistency in literature is observed concerning the association of mtDNA 
content with type 2 diabetes (10;11). In our study we could not detect a relation 
between mtDNA content in blood and prevalent type 2 diabetes in a case / control 
setup. Post-hoc power calculations showed that we had >95% power to detect an 
effect comparable to the results of Lee H.K. et al (mitochondrial content 35% lower 
in cases of type 2 diabetes) (10) and 80% power to detect a difference of at least 
10%. Therefore, we conclude that mtDNA content in blood is not associated with 
type 2 diabetes in our sample selection. 
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Incident type 2 diabetes and mitochondrial DNA content 
In order to analyze the relation between mtDNA content and incident cases of type 
2 diabetes we analyzed two prospective studies, but we could not detect a 
consistent association with incident type 2 diabetes. A previous study had 
suggested a 25% decrease in converters (10). We had >95% power to detect a 
similar effect in both prospective 1 and prospective 2 (Botnia and Rotterdam) 
studies. This indicates that mtDNA content in blood is not a good predictor of future 
type 2 diabetes. While the prospective 1 study shows a trend towards decreased 
risk for type 2 diabetes with increased mtDNA content, the prospective 2 study 
shows an opposite effect. This might be caused by the differences between the 
studies. For instance, participants from the prospective 1 sample are younger, than 
those of the prospective 2 sample. Furthermore, there are more IGT and IFG 
subjects in the non-converter group of the prospective 1 sample, compared to the 
prospective 2 sample. However, analyzing only NGT subjects does not change the 
outcome.  
We conclude that mtDNA content in blood is not associated with incident type 2 
diabetes, which argues against previous observations where low mtDNA content in 
blood was associated with type 2 diabetes, triglyceride storage, glucose 
homeostasis, insulin sensitivity and insulin secretion (10;12-15). A major difference 
between our and previous studies is the difference in ethnicity. All positive findings 
arose in Asian participants from Korea, while no associations were observed in 
Caucasians (10-14). Our data indicate that mtDNA content in blood is not useful as 
predictor of type 2 diabetes in Caucasians. We cannot rule out any effects of 
mtDNA content in other tissues like muscle, pancreas and adipose tissue on type 2 
diabetes and related traits like insulin resistance and secretion. Muscle seems a 
highly relevant tissue to examine mitochondrial function since associations with 
mitochondrial activity and insulin resistance are observed (35;36) and it has 
already been reported that mtDNA content decreases with aging in muscle, but 
also in pancreas, liver and blood (5;37-39). It seems that the decline in mtDNA 
content in muscle is faster than in blood. This may be related to the high level of 
oxidative metabolism in these tissues. Furthermore, it is speculated that the faster 
proliferative rate of hematopoietic stem cells provides them with the opportunity to 
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remove damaged mtDNA and perhaps a better maintenance of mtDNA 
copynumber (37;38).  
In our pooled dataset we observed a negative correlation between mtDNA content 
and age, which was male specific. To our knowledge, we are the first to show that 
the decline in mtDNA content might be male specific. The observed gender effect 
on mtDNA content, also observed by Xing J et al (6), is probably caused by this 
gender specific correlation between mtDNA content and ageing. One might 
speculate that overall mitochondrial fitness is better retained in females, which 
might explain the observed difference in life span between males and females. 
However, this hypothesis needs further investigation. The association between 
mtDNA content and BMI was very weak and was not observed by others (10-15). 
Therefore, it is likely that this is not a true association.  
 
In summary, we have confirmed the heritability of mtDNA content, but could not 
find evidence for an association of mtDNA content in blood with prevalent or 
incident type 2 diabetes. The observed decline in mtDNA content in males might 
suggest enhanced mitochondrial fitness in elderly women. However, this needs 
further study in more suitable cohorts and experimental settings. 
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Supplementary table S1. Regression of mitochondrial DNA content with clinical variables 
 
Twins / 
Heritability study 
(n = 403) 
Case / Control 
study 
(n = 329) 
Prospective 1 
study 
(n = 444) 
Prospective 2 
study 
(n = 238) 
Age 
-0.001 
(-0.003 to 0.001) 
0.35 
 
-0.002 
(-0.004 to 0.0001) 
0.06 
 
-0.0008 
(-0.002 to 0.0001) 
0.09 
 
-0.002 
(-0.006 to 0.002) 
0.29 
 
BMI 
-3.05 
(-5.17 to -0.92) 
0.005 
 
0.55 
(-2.18 to 3.27) 
0.69 
 
-0.78 
(-3.31 to 1.76) 
0.55 
 
-2.26 
(-4.57 to 0.04) 
0.05 
 
WHR 
-0.03 
(-0.08 to 0.02) 
0.27 
 
0.02 
(-0.08 to 0.13) 
0.68 
 
0.01 
(-0.04 to 0.05) 
0.77 
 
0.01 
(-0.05 to 0.06) 
0.85 
 
0hr gluc 
0.49 
(0.08 to 0.91) 
0.02 
 
0.27 
(-0.28 to 0.81) 
0.34 
 
0.19 
(-0.17 to 0.55) 
0.29 
 
n.a. 
2hr gluc n.a. 
1.04 
(-0.94 to 3.02) 
0.30 
0.72 
(-0.45 to 1.90) 
0.23 
n.a. 
Regression coefficients are shown with 95% CI and p-values. 
WHR: Waist Hip Ratio 
n.a.: not available 
For the case / control study, only NGT participants are included (n = 175) 
Regression coefficients, 95% CI and p-values are shown. 
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supplementary table S2. Gender effect on mitochondrial DNA content in healthy participants 
Study Male Female 
Twins / Heritability 1.01 (0.96 to 1.06) 1.01 (0.97 to 1.06) 
p-value 0.98 
Case / Control 0.98 (0.94 to 1.03) 0.98 (0.92 to 1.01) 
p-value 0.95 
Prospective 1 0.97 (0.93 to 1.01) 1.02 (0.98 to 1.07) 
p-value 0.07 
Prospective 2 0.92 (0.87 to 0.97) 1.04 (0.98 to 1.09) 
p-value 0.002 
 
Pooled 0.96 (0.93 to 0.98) 1.01 (0.98 to 1.04) 
p-value 0.007 
Relative mitochondrial DNA content, normalized using the average mtDNA content of every 
independent study sample are shown with 95% CI and p-values. Netherlands Twin Register is 
excluded from the pooled sample, since DNA extractions are from buccal cells. 
Estimated mean mitochondrial DNA content and 95% CI are calculated using generalized estimating 
equations with adjustment for age and BMI. 
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Abstract 
Aims/hypothesis  
Variation in fasting plasma glucose (FPG) within the normal range is a known risk 
factor for the development of type 2 diabetes. Several reports have shown that 
genetic variation in the genes for glucokinase (GCK), glucokinase regulatory 
protein (GCKR), islet-specific glucose 6 phosphatase catalytic subunit-related 
protein (G6PC2) and melatonin receptor type 1B (MTNR1B) is associated with 
FPG. In this study we examined whether these loci also contribute to type 2 
diabetes susceptibility. 
Methods  
A random selection from the Dutch New Hoorn Study was used for replication of 
the association with FGP (2361 non-diabetic participants). For the genetic 
association study we extended the study sample with 2628 participants with type 2 
diabetes. Risk allele counting was used to calculate a four-gene risk allele score for 
each individual. 
Results  
Variants of the GCK, G6PC2 and MTNR1B genes but not GCKR were associated 
with FPG (all, p≤0.001; GCKR, p= 0.23). Combining these four genes in a risk 
allele score resulted in an increase of 0.05 mmol/l (0.04–0.07) per additional risk 
allele (p=2×10−13). Furthermore, participants with less than three or more than five 
risk alleles showed significantly different type 2 diabetes susceptibility compared 
with the most common group with four risk alleles (OR 0.77 [0.65-0.93], p=0.005 
and OR 2.05 [1.50-2.80], p=4×10–6 respectively). The age at diagnosis was also 
significantly associated with the number of risk alleles (p=0.009). 
Conclusion  
A combined risk allele score for single-nucleotide polymorphisms in four known 
FPG loci is significantly associated with FPG and HbA1c in a Dutch population-
based sample of non-diabetic participants. Carriers of low or high numbers of risk 
alleles show significantly different risks for type 2 diabetes compared with the 
reference group.
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Introduction 
Variation in fasting plasma glucose (FPG) levels within the normal range are 
associated with an increased risk of developing type 2 diabetes and coronary heart 
disease (1;2). Furthermore, it is known that FPG is partially genetically determined 
(3). Several loci influencing FPG levels have been identified. These loci encode 
glucokinase (GCK), glucokinase regulatory protein (GCKR) and islet-specific 
glucose 6 phosphatase catalytic subunit-related protein (G6PC2) (4-10). Recently, 
the gene encoding melatonin receptor type 1B (MTNR1B) was identified as a fourth 
locus influencing FPG (11-13). In this study we investigated the combined effect of 
these loci on FPG levels in the Netherlands and analysed their single and 
combined effects on the risk of type 2 diabetes. 
 
Methods 
Study samples 
 
Study sample for continuous trait analysis  
For this part of the study we used participants from the ongoing New Hoorn Study, 
a population-based cohort study in the Netherlands, which examines potential 
determinants of glucose intolerance and related disorders (14;15). From this study, 
2361 non-diabetic white participants (46% male, aged 53±7 years) were selected 
from the original random sample of the population register of the town of Hoorn, the 
Netherlands. Glucose tolerance status was assessed with OGTT using the 1999 
WHO criteria (16).  
 
Case–control sample for genetic association with type 2 diabetes  
As a control sample we used all participants with normal glucose tolerance from 
the above-mentioned sample (n=2041). Subjects with impaired glucose tolerance 
(IGT) and/or impaired fasting glucose (IFG) (n=320) were excluded from the control 
group because they have an increased risk of type 2 diabetes.  
For the case sample we used all known (n=90) and newly identified (n=90) cases 
from the New Hoorn Study. To improve power we added cases from Diabetes Care 
System West Friesland (DCS, n=1906) (17). The DCS aims to improve diabetes 
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care by coordinating diabetes care, involving all caregivers and providing education 
for patients in order to improve patient empowerment. Patients are referred to the 
DCS by their physicians and are from the same geographical region as those 
taking part in the New Hoorn Study. We also included 542 type 2 diabetes patients 
from the diabetes clinics at Leiden University Medical Centre (Leiden, the 
Netherlands) and VU University Medical Centre (Amsterdam, the Netherlands), 
who were referred to the clinic by their physicians. In total we selected 2628 
participants with type 2 diabetes (55% males, aged 64±11 years) for the case–
control study. All participants in our study were of white ethnicity. The study was 
approved by the appropriate medical ethics committees and was in accordance 
with the principles of the Declaration of Helsinki. 
 
Genotyping and quality control 
Based on previous publications, we selected the single-nucleotide polymorphisms 
(SNPs) rs1799884 in GCK (4), rs1260326 (P446L) in GCKR (7), rs560887 in 
G6PC2 (9) and rs10830963 in MTNR1B (11-13) for genotyping with Taqman SNP 
genotyping assay (Applied Biosystems, Foster City, CA, USA). All genotype 
frequencies were similar between the case subgroups. For quality control the allelic 
discrimination plots were visually observed for good clustering. Plates with bad 
clustering or a success rate below 95% were repeated. Next, we assessed Hardy–
Weinberg equilibrium (p>0.05) and genotyped approximately 5% duplicate 
samples, which all showed identical genotypes.  
 
Statistical analysis 
Differences in FPG and other clinical variables (HbA1c, 2 h glucose, triacylglycerol, 
LDL, HDL, total cholesterol, BMI and waist–hip ratio) were analysed in non-diabetic 
participants using linear regression, adjusted for BMI, age and sex as possible 
confounders. All analyses were performed using an additive model, because 
previous studies had shown that this model was the best fit. In order to combine 
the effects of all SNPs, risk alleles were counted and used as a sum score (18). A 
risk allele was defined as an allele that results in an increased FPG as described in 
the literature. Differences in genotype distribution, allele frequency and risk allele 
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scores between participants with normal glucose tolerance and those with type 2 
diabetes were compared using standard contingency tables with Fisher’s exact 
test, and allelic ORs were calculated with logistic regression adjusted for age, sex 
and BMI. Subjects with either IGT or IFG were excluded from this analysis. Using 
Bonferroni correction for multiple hypothesis testing, p<0.001 was considered 
statistically significant for association of FPG loci with clinical variables (36 tests). 
For the case–control study, p<0.01 was considered significant (four tests). All 
statistics were calculated using SPSS 16.0 (SPSS, Chicago, IL, USA). 
 
Power calculations 
Power calculations were performed using Quanto (19). We had an estimated 
power of 80% to detect a minimal per allele effect in clinical variables between 
0.056 and 0.069 mmol/l, depending on allele frequency (α=0.001). For the 
association study with type 2 diabetes we had an estimated power of 80% to detect 
a minimal OR between 1.13 and 1.16 for single gene effects (α=0.01). For all 
power calculations we assumed an additive model. 
 
Table 1 Association of SNPs with FPG (n=2361) and type 2 diabetes (n=4669) 
FPG, mmol/l (genotype count) T2D OR Locus AA AB BB 
Effect/allele 
mmol/l Padd 95% CI PAdd 
GCK 5.39±0.01  (1523) 
5.45±0.02  
(620) 
5.47±0.05  
(65) 
0.06 
0.03 to 0.09 0.001 
1.12 
1.00–1.25 0.06 
GCKR 5.35±0.03  (267) 
5.39±0.01  
(956) 
5.38±0.01  
(924) 
0.01 
−0.02 to 0.03 0.23 
0.94 
0.86–1.02 0.13 
G6PC2 5.32±0.03 
 (218) 
5.36±0.01 
 (930) 
5.43±0.01 
 (1077) 
0.06 
0.04 to 0.09 5×10
−6
 
0.96 
0.87–1.05 0.32 
MTNR1B 5.37±0.01  (1269) 
5.44±0.01  
(891) 
5.52±0.04 
(135) 
0.08 
0.05 to 0.11 7×10
−8
 
1.12 
1.02–1.23 0.02 
Estimated FPG levels (mean±SD) per genotype are adjusted for age, sex and BMI 
Effect per allele on FPG levels, 95% CI and p values, adjusted for age, sex and BMI, were generated by linear 
regression 
The B genotype carries the risk allele 
Odds ratios are for associations of independent SNPs with type 2 diabetes and were calculated based on allele 
frequency in 2041 controls and 2628 type 2 diabetes participants 
T2D, type 2 diabetes 
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Results 
All SNPs passed quality control guidelines. Associations between SNPs and 
clinical variables were analysed in the non-diabetic participants only. Results of 
association with FPG levels were comparable to those reported in the literature (all 
p≤0.001), except for GCKR, for which we could not detect a significant effect on 
FPG levels (p=0.23; results shown in Table 1). However, GCKR showed nominal 
evidence for decreased 2 h glucose, but did not reach a formally significant p value 
(p=0.008; see Electronic supplementary material [ESM] Table 1). Furthermore, 
GCK and G6PC2 showed increased HbA1c levels (p=5×10−8 and 3×10−5; ESM 
Table 1). In line with our FPG results, GCKR was not associated with HbA1c levels 
(p=0.50). However, we did confirm the previously reported association of the T 
allele of rs1260326 (GCKR) with increased triacylglycerol levels (p=9×10−7; ESM 
Table 1) (5). Other clinical variables were not associated with any of the analysed 
variants (ESM Table 1). We analysed the combined effect of all SNPs by 
calculating the risk allele score for each individual. We observed a combined effect 
of the risk alleles on FPG levels. The increase in FPG level per additional risk allele 
was 0.05 mmol/l (0.04–0.07 mmol/l), p=2×10−13 (Fig. 1a). A similar result was 
Fig. 1 Combined effect of GCK, GCKR, G6PC2 and MTNR1B on FPG and HbA1c in non-diabetic 
participants from the New Hoorn Study. 
A Fasting plasma glucose. Numbers within the bars are numbers of participants per allele group. The per 
allele effect was 0.05 (0.04–0.07) mmol/l (p=2×10−13). 
Error bars represent 95% CI. 
B HbA1c. Numbers within the bars represent the number of participants per allele group. The per allele 
effect was 0.03% (0.02–0.04) (p=5×10−10). 
Error bars represent 95% CI 
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observed for HbA1c: 0.03% (0.02–0.04) increase per additional risk allele, 
p=5×10−10 (Fig. 1b). We also analysed whether the rate of the age-related increase 
in FPG was affected by the number of risk alleles. However, we did not observe 
any differences in these rates between the risk allele scores in our cross-sectional 
data set (ESM Fig. 1). Separate analysis of only the participants with normal 
glucose tolerance (n=2041) did not alter any of the results (data not shown) 
Next, we analysed the association of these single variants and the risk allele score 
with type 2 diabetes susceptibility. Only rs10830963 (MTNR1B) and rs1799884 
(GCK) showed weak evidence for association with type 2 diabetes (p=0.02 and 
p=0.06 respectively; Table 1 and ESM Table 2). Risk allele scores were calculated 
for the participants with normal glucose tolerance and those with type 2 diabetes 
and all risk allele groups were compared with the reference group having four risk 
alleles, since this was the most common group (31%). The lower risk allele groups 
showed a protective effect on type 2 diabetes, while the risk allele groups with 
more than four risk alleles showed an increased risk of type 2 diabetes (Table 2). 
Those with fewer than three risk alleles had a significantly reduced risk of type 2 
diabetes (OR 0.77 [0.65-0.93], p=0.005) whereas those with more than five had a 
significantly increased risk of type 2 diabetes compared with the reference group 
(OR 2.05 [1.50–2.80], p=4×10−6). Adjustment for age, sex and BMI did not alter the 
results. 
We also noted a significant correlation with the age at diagnosis of type 2 diabetes 
in our study sample. We observed a per allele effect of −0.46 (−0.80 to −0.11) 
years in age at diagnosis per additional risk allele (p=0.009) (Table 2). At the 
extremes of the distribution, i.e. 0 or 1 versus 6–8 risk alleles, there was a 
difference of almost 4.5 years in age at diagnosis between the two groups 
(p=0.002) (Table 2). 
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Discussion 
Several studies have shown that SNPs in GCK, GCKR, G6PC2 and MTNR1B are 
associated with FPG levels (4-7;9;11-13;20). In this study we replicated these 
findings in a Dutch population, with the exception of the association of GCKR with 
FPG. However, our results for GCKR are in the same direction as those of most 
other studies and it should be noted that some other recent publications reported 
considerable variability in effect size between different samples (8) or failed to 
replicate this observation (11). GCK and G6PC2 were associated with HbA1c in our 
study, which confirms previous observations (13;21). 
We observed a significant combined effect of all variants on FPG levels. This 
confirms a recent observation in a French study (13). The association of FPG 
levels with the risk allele count was also reflected in increased HbA1c levels, 
arguing against previous findings in which it was suggested that FPG and HbA1c 
have independent underlying risk loci (22;23). Our cross-sectional data suggest 
that these loci cause a physiological disturbance of glucose homeostasis by raising 
the set point of insulin secretion, leading to an elevation of FPG depending on the 
number of risk alleles present, which is not further affected by ageing. However, 
longitudinal studies and a wider age span would be needed to confirm this 
observation. 
To our knowledge, this is the first report showing that the analysed loci have a 
combined effect on type 2 diabetes susceptibility, although the contribution of each 
individual variant to the risk of type 2 diabetes is very low or undetectable (Table 
Table 2 Association of risk allele scores with type 2 diabetes 
Count (frequency) Risk 
alleles Controls (n=2041) 
Cases 
(n=2628) 
Age at 
diagnosisa 
(years, SD) 
OR for T2D (95% CI) p value T2D 
0 or 1 76 (4.2) 115 (4.9) 57.5±1.1 0.75 (0.55–1.02) 0.07 
2 243 (13.5) 352 (15.0) 57.3±0.6 0.78 (0.64–0.95) 0.02 
3 522 (29.0) 667 (28.4) 56.1±0.5 0.89 (0.76–1.04) 0.14 
4 605 (33.6) 685 (29.1) 55.6±0.4 1.00 ref 
5 288 (16.0) 381 (16.2) 56.1±0.6 1.17 (0.97–1.41) 0.11 
6-8 65 (3.6) 151 (6.4) 52.9±0.9 2.05 (1.50–2.80) 4×10-6 
a Age at diagnosis was available for 2132 participants with type 2 diabetes 
Betaage at diagnosis=−0.46 (−0.80 to −0.11) years, p=0.009 adjusted for sex 
OR for type 2 diabetes for <3 versus 4 risk alleles was 0.77 (0.65–0.93), p=0.005 
OR for type 2 diabetes for >4 versus 4 risk alleles was 1.33 (1.12–1.58), p=0.001
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1). Our data show that carriers of fewer than three risk alleles are at decreased risk 
of type 2 diabetes whereas those with more than five risk alleles have increased 
susceptibility to type 2 diabetes compared with the most common risk allele group 
of four risk alleles. We also noted a significantly different age at diagnosis between 
the different groups, indicating that the number of risk alleles also influences the 
age at which the disease becomes manifest. This might also have implications for 
the development of complications. If replicated, our results imply that these loci not 
only influence FPG levels, probably through an altered set point for glucose at 
which an insulin response is elicited, but also jointly increase the risk of type 2 
diabetes and the age at diagnosis.  
In conclusion, we replicated the combined effect of GCK, GCKR, G6PC2 and 
MTNR1B risk alleles with FPG. Furthermore, we showed that the risk allele score is 
also associated with HbA1c and that carriers of a low or high number of risk alleles 
have significantly different susceptibilities to the development of type 2 diabetes 
and age at diagnosis of the disease. 
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Supplementary table s1. Association of GCK, GCKR, G6PC2 and MTNR1B with clinical variables in  
Variant FPG (mmol / L) 
2hrG 
(mmol / L) 
HbA1C 
(%) 
TG 
(mmol / L) 
GCK (rs1799884) 
GG 5.39 (0.01) 5.37 (0.04) 5.34 (0.01) 1.39 (0.02) 
GA 5.45 (0.02) 5.49 (0.06) 5.40 (0.01) 1.39 (0.03) 
AA 5.47 (0.05) 5.68 (0.18) 5.44 (0.03) 1.31 (0.09) 
p-value 0.001 0.06 5·10-8  0.86a 
GCKR (rs1260326) 
TT 5.35 (0.03) 5.40 (0.08) 5.33 (0.02) 1.56 (0.05) 
TC 5.39 (0.01) 5.36 (0.04) 5.35 (0.01) 1.39 (0.02) 
CC 5.38 (0.01) 5.19 (0.04) 5.35 (0.01) 1.30 (0.02) 
p-value 0.23 0.008 0.50 9·10-7a 
G6PC2 (rs560887) 
AA 5.32 (0.03) 5.42 (0.09) 5.30 (0.02) 1.33 (0.05) 
AG 5.36 (0.01) 5.34 (0.05) 5.34 (0.01) 1.37 (0.03) 
GG 5.43 (0.01) 5.33 (0.04) 5.37 (0.01) 1.39 (0.02) 
p-value 5·10-6 0.67 3·10-5 0.30a 
MTNR1B (rs10830963) 
CC 5.37 (0.01) 5.40 (0.04) 5.35 (0.01) 1.38 (0.02) 
CG 5.44 (0.01) 5.38 (0.05) 5.37 (0.01) 1.38 (0.03) 
GG 5.52 (0.04) 5.50 (0.12) 5.40 (0.02) 1.45 (0.07) 
p-value 7·10-8 0.62 0.01 0.26a 
Association of Fasting Plasma Glucose (FPG), 2 hours glucose (2hrG), HbA1C, triglycerides (TG), LDL, HDL,  
Data represent estimated means, adjusted for age, gender and BMI and standard deviations are given. 
a: Non transformed values are shown. P-values are calculated with 10Log transformed triglyceride values. 
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non diabetic subjects from the NHS (n = 2361). 
LDL 
(mmol / L) 
HDL 
(mmol / L) 
TC 
(mmol / L) 
BMI 
(kg / m2) WHR 
 
3.31 (0.02) 1.53 (0.01) 5.45 (0.03) 25.97 (0.10) 0.89 (0.001) 
3.36 (0.04) 1.51 (0.02) 5.50 (0.04) 25.91 (0.15) 0.89 (0.002) 
3.29 (0.11) 1.48 (0.05) 5.36 (0.12) 25.89 (0.47) 0.89 (0.006) 
0.39 0.46 0.40 0.94 0.79 
 
3.33 (0.05) 1.52 (0.02) 5.54(0.06) 25.85 (0.23) 0.89 (0.003) 
3.32 (0.03) 1.52 (0.01) 5.46 (0.03) 25.78 (0.12) 0.89 (0.002) 
3.35 (0.03) 1.54 (0.01) 5.47 (0.03) 25.94 (0.12) 0.89 (0.002) 
0.76 0.37 0.53 0.66 0.63 
 
3.23 (0.06) 1.57 (0.03) 5.39 (0.07) 25.87 (0.26) 0.89 (0.004) 
3.31 (0.03) 1.51 (0.01) 5.44 (0.03) 25.93 (0.12) 0.89 (0.002) 
3.36 (0.03) 1.52 (0.01) 5.50 (0.03) 25.87 (0.12) 0.89 (0.002) 
0.12 0.18 0.18 0.93 0.99 
 
3.34 (0.03) 1.52 (0.01) 5.48 (0.03) 25.88 (0.11) 0.89 (0.001) 
3.28 (0.03) 1.54 (0.01) 5.43 (0.03) 25.93 (0.13) 0.89 (0.002) 
3.34 (0.08) 1.48 (0.03) 5.47 (0.08) 26.63 (0.33) 0.89 (0.004) 
0.29 0.27 0.54 0.09 0.82 
total cholesterol (TC), BMI and waist-hip ratio (WHR) with SNPs in GCK, GCKR, G6PC2 and MTNR1B.  
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Supplementary table s2. Genotyping results of the independent SNPs in 2041 controls and 2628 cases. 
Allele frequency risk allele 
(AA, AB, BB) SNP Gene risk allele 
controls (n) cases (n) 
OR (95% CI) P-value 
rs1799884 
 
GCK 
 
A 
 
16.8 (641) 
1326, 531, 55 
 
18.4 (917) 
1668, 743, 87 
 
1.12 
1.00 – 1.25 
 
0.06 
 
rs1260326 
 
GCKR 
 
C 
 
65.8 (2562) 
235, 864, 848 
 
64.2 (3232) 
313, 1174, 1029 
 
0.94 
0.86 – 1.02 
 
0.13 
 
rs560887 
 
G6PC2 
 
G 
 
69.6 (2750) 
192, 816, 967 
 
68.6 (3502) 
263, 1074, 1214 
 
0.96 
0.87 – 1.05 
 
0.32 
 
rs10830963 MTNR1B G 25.0 (994) 1111, 764, 115 
27.1 (1377) 
1343, 1011, 183 
1.12 
1.02 – 1.23 0.02 
Allele frequencies (counts) and genotype counts (AA, AB, BB) are shown. B represents the risk allele. 
 
40-45 45-50 50-55 60-6555-60
Supplementary Figure 1: Age related increase in FPG in non-diabetic subjects. 
For ease of interpretation we have divided the non-diabetic subjects into four groups 
depending on the number of risk alleles. Group 1, 0 to 2 risk alleles (n=359); group 2, 3 
risk alleles (n=580); group 3, 4 risk alleles (n=652) and group 4, >5 risk alleles (n=393). 
Unadjusted trend lines for each group are shown. Beta’s with (95% CI) are calculated 
with linear regression adjusted for gender and BMI. Group 1: β = 0.013 (0.007-0.019); 
Group 2; β = 0.011 (0.006-0.016); Group 3; β = 0.011 (0.007-0.016); Group 4; β = 
0.013 (0.007-0.019); all P<1.0*10-4) 
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This thesis deals with a genetic study on the involvement of mitochondria in 
setting the risk for type 2 diabetes and related parameters. It comprises three 
themes: 
(1) Nuclear encoded mitochondrial proteins (chapters 2 and 3); 
(2) Mitochondrial DNA content and type 2 diabetes (chapter 4); 
(3) Genes regulating fasting plasma glucose concentrations (chapter 5). 
 
Part 1: Nuclear encoded mitochondrial proteins (chapters 2 and 3) 
In Chapter 2 I describe the association study of the mitochondrial leucyl-tRNA 
synthetase gene (LARS2) with type 2 diabetes. The LARS2 gene is a candidate 
gene for type 2 diabetes involved in the same biochemical pathway as the 
mitochondrial tRNA-Leu(UUR) gene. Mutations in the latter gene are low frequency 
high penetrance mutations for the maternally inherited diabetes and deafness 
syndrome. 
Previously an H324Q variant in this gene was found to be associated with type 2 
diabetes in four independent populations from the Netherlands and Denmark (1). 
This variant is potentially able to affect proper function of the mitochondrial leucyl 
tRNA synthetase as we obtained biochemical evidence that the H324Q variant may 
lead to increased acylation of mitochondrial tRNA-Leu with Isoleucine (E. Reiling et 
al., unpublished). As an extension of our previous finding we analyzed common 
tagging SNPs (MAF > 0.05) and low frequency SNPs (MAF 0.01 - 0.05) in LARS2 
in the Dutch Hoorn study. Potential signals, including the previously identified 
H324Q variant, were followed up in up to 35715 subjects from the Netherlands, 
Denmark, Sweden, Finland and the UK. Access to these samples was by 
collaboration with J.M. Dekker, G. Nijpels, A.G. Uitterlinden, M.H. Hofker, O. 
Pedersen, T. Hansen, L. Groop and M.I. McCarthy. After follow up no putative 
associations remained significant, including the H324Q variant. These data exclude 
the LARS2 gene as a major type 2 diabetes susceptibility gene. In order to 
elucidate the failure of replication of the previously found association of H324Q with 
type 2 diabetes we analyzed our data for heterogeneity by stratification for several 
variables like age and geographic location of study samples. Given the potential 
role of mitochondria in ageing the variant may affect life expectancy in some 
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subgroups of the cohorts. In addition, the frequency of some genetic variants have 
been found to exhibit a geographic north-south trend. A decrease in MAF at 
increasing age was observed for type 2 diabetes subjects in most but not all study 
samples. This could indicate an increased mortality in type 2 diabetes subjects 
carrying the H324Q risk allele, but this did not reach formal levels of statistical 
significance. Furthermore, a MAF gradient from south to north was observed in the 
UK. However, this was not observed in our initial study (1) and additional samples 
from The Netherlands, Denmark, Sweden and Finland, making this an unlikely 
explanation for the initial false positive finding. Most likely, the first finding was a 
false positive, caused by chance. These findings highlight the potential pitfalls one 
can encounter when analyzing low frequency variants. 
 
In chapter 3 I describe a candidate gene study on the association of variants in 
nuclear-encoded mitochondrial protein genes with type 2diabetes. In total 13 
candidate genes were selected. The rationale for selecting these genes is 
accumulating evidence that mitochondria play a causal role in the onset of type 2 
diabetes. For instance a 3243A>G mutation in the mitochondrial tRNA-Leu(UUR) 
gene is associated with maternally inherited diabetes and deafness, a specific 
subtype of diabetes. Carrier frequency of this mutation is 0.3-2%, depending on 
ethnicity. In addition, a number of other rare point mutations in mitochondrial DNA 
(mtDNA) are high penetrance diabetogenic mutations (2). However, common SNPs 
in mtDNA did not show evidence for association with type 2 diabetes (3;4). This 
makes it unlikely that additional, polymorphisms in mtDNA exist which contribute to 
type 2 diabetes. However, mitochondrial dysfunction has been shown in muscle 
from type 2 diabetes patients and their non-diabetic, insulin resistant, first degree 
relatives (5-7). Since the majority of mitochondrial proteins are encoded by the 
nucleus, we focussed on nuclear encoded mitochondrial genes that are thought to 
be key players in mitochondrial maintenance and function. We genotyped tagging 
SNPs covering all common variation in these candidate genes (CEU population, 
MAF > 0.05) in our first stage sample (the Dutch Hoorn Study, n = 999). Potential 
signals (p < 0.05) were followed up in the second stage comprising of Dutch 
samples from the New Hoorn Study, Breda Study and ERGO study (n = 10164). 
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Only one SNP (rs2522138 in SIRT4) remained significant, but after extending the 
second stage with a sample from Denmark (n = 1220) the signal was no longer 
significant. Therefore, I conclude that common variation in the selected candidate 
genes is not associated with type 2 diabetes. Although the first stage was 
underpowered to detect modest associations (80% to detect an OR of 1.45, MAF = 
0.1), results were in line with results from Genome Wide Association Studies 
(GWAS), making it unlikely that common variation in our candidate genes is 
associated with type 2 diabetes (8-12). This study underlines the importance of 
extensive replication of novel association signals.  
Since we selected only 13 candidate genes and the total pool of mitochondrial 
protein is expected to be approximately 1500 (13), we cannot conclude from our 
data that common SNPs in nuclear encoded mitochondrial genes do not contribute 
to the development of type 2 diabetes. However, nuclear encoded mitochondrial 
proteins are also not among the top hits of GWAS (8-12). Since the DIAGRAM 
meta-analysis used LD information from the HapMap database and covered 
~2,000,000 SNPs, a large proportion of common DNA sequence variation is 
covered by this analysis. Also this study did not show evidence for association of 
nuclear encoded mitochondrial proteins with type 2 diabetes (12). Therefore, it 
seems likely that common genetic defects in nuclear encoded mitochondrial 
proteins do not have a major contribution to type 2 diabetes susceptibility. 
However, while GWAS, like the DIAGRAM meta-analysis, are well powered to 
identify association of common SNPs with type 2 diabetes (MAF > 0.05), they are 
underpowered to detect associations of low frequency and rare variations (MAF < 
0.05) with type 2 diabetes considering modest effect sizes. Moreover, genotype 
data from the HapMap database about the Caucasian population is based on 90 
subjects (CEU population) (14). Therefore, it is likely that low frequency variation 
was partially missed during sequencing of these 90 subjects and subsequently 
these are not analysed for association with type 2 diabetes using LD. 
Taken together, it is not likely that common SNPs in nuclear encoded mitochondrial 
proteins predispose to type 2 diabetes susceptibility. However, this conclusion 
cannot be drawn for low frequency variation. Since the HapMap database does not 
provide sufficient genotype data about that kind of genetic variation, resequencing 
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of large samples (>100 subjects) should be applied in order to identify low 
frequency variation prior to large scale genotyping. Currently, the 1000 genomes 
consortium (www.1000genomes.org) is aiming to achieve a nearly complete 
catalogue of common human genetic variation with a MAF above 0.01. Three sets 
of 400-500 individuals from broad geographic regions are being resequenced and 
the data will be published on a free accessible database. This project will 
potentially generate helpful information, which can further improve our 
understanding of the involvement of nuclear encoded mitochondrial proteins, 
including the influence of low frequency variation (MAF = 0.01 – 0.05). However, 
our study concerning the LARS2 gene (chapter 2 of this thesis), illustrates the 
pitfalls of studying low frequency variation. Population heterogeneity caused by for 
instance age or geographic stratification can bias the observations resulting in false 
positive (or negative) findings. Therefore, caution should be taken when analyzing 
low frequency variation. Very large, homogeneous study samples (n > 30000) will 
be needed, not only to obtain sufficient power to identify diabetogenic SNPs with 
modest impact, but also to confirm novel findings, since these are easily biased by 
above mentioned heterogeneity. When analyzing their data, researchers should be 
aware of these pitfalls. Sequencing will also provide more insight in another form of 
genetic variation; the so-called copy number variations (CNV). CNVs are deletions 
or insertions of stretches of DNA sequences. It is likely that these CNVs affect 
gene function and therefore disease susceptibility. Until now, little is known about 
the existence and role of CNVs. Sequencing projects will reveal more detailed 
information about this issue (15). It has been shown that the smaller and common 
CNVs are inherited like SNPs (16). If their effect on T2DM is also comparable to 
that of common SNPs (OR < 1.5), they might have been undetected by family 
studies. However, large CNVs with a higher impact on type 2 diabetes 
susceptibility (OR > 1.5) would have been detected by family studies. On the other 
hand, low frequency CNVs with a modest impact on type 2 diabetes mellitus, might 
also been missed previously.  
For analyzing rare variation (MAF < 0.01) a different strategy has to be applied, 
since case-control studies will be underpowered for this. Resequencing and 
genotyping should be performed in families with a high prevalence of type 2 
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diabetes to study rare variation, the so-called linkage study as explained in the 
introduction of this thesis. The very rare variations will potentially result in a 
technical problem because the MAF will almost reach the same value as the 
genotyping error, resulting in yet another difficulty in analyzing rare variation. The 
theoretical arrangement of rare, low frequency and common variation is 
schematically shown in figure 1. Common variants with high impact on type 2 
diabetes are not expected, because they would have been detected in GWAS. 
Figure 1. arrangements of rare, low frequency and common variation  
Addapted from McCarthy MI et al, Nat Rev Genet. 2008 May 
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In conclusion, our study excludes the association of common variation in 14 
selected candidate genes including the LARS2 gene, with type 2 diabetes. All 
these genes encode for mitochondrial proteins involved in mitochondrial protein 
synthesis and biogenesis. Furthermore, it is not likely that common variation in 
other mitochondrial targeted genes is associated with type 2 diabetes, based on 
GWAS data. However, we cannot exclude the involvement of low frequency and 
rare variations in these genes even when they have relative high diabetogenic 
potential (OR > 1.4). This should be elucidated in future research. 
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Part 2: Mitochondrial DNA content and type 2 diabetes (chapter 4) 
Proper mitochondrial function contributes to many cellular processes related to 
maintenance of glucose homeostasis, such as insulin resistance of muscle, 
glucose-induced, insulin secretion, apoptosis of pancreatic beta-cells, removal of 
fatty acids by beta-oxidation and setting the energy status of the brain. In chapters 
2 and 3 of this thesis, I described our findings that common variants in key-
mitochondrial proteins are unlikely to be linked to type 2 diabetes susceptibility. 
Another factor that determines mitochondrial activity within a cell is variation in the 
number of mitochondrial DNA (mtDNA) molecules per cell, expressed as number of 
mtDNA molecules per nuclear genome. For that reason we also analyzed mtDNA 
content in blood in relation to the risk of an individual for developing type 2 
diabetes. This study is described in chapter 4. 
In view of the situation that the risk for diabetes has a genetic component we first 
assessed whether mtDNA content is determined by heritability. We found a 
heritability of 35% (19 - 48) in buccal cells. This confirms findings of others, which 
showed comparable results in blood (17;18). We could not detect an association of 
mtDNA content in blood with prevalent type 2 diabetes, incident type 2 diabetes or 
related traits. This contradicts previously published studies, in which it was shown 
that a low mtDNA content precedes type 2 diabetes onset and is associated with 
insulin resistance, glucose metabolism, insulin secretion and patterns of triglyceride 
storage (19-22). However, our results are supported by another study, in which no 
differences were observed in mtDNA content between first degree relatives of type 
2 diabetes patients and control participants without family history of type 2 diabetes 
(23). The original studies are often much smaller than our study. Therefore, it might 
be possible that those were false positives, caused by bias during sample 
selection. Another possibility is that differences in ethnicity causes the discrepancy 
between different studies, since associations of mtDNA content with type 2 
diabetes and related traits are only observed in people of Asian descent. We did 
observe evidence for an inverse relation of mtDNA content with age, which is in 
line with previous observations in blood and muscle (17;24). However, our results 
indicate that this is specific for males, resulting in a lower mtDNA content in elderly 
males compared to elderly females. 
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One of the drawbacks of our and previous studies, is that blood was used for DNA 
extraction. Since this is a heterogeneous cell type, results can be biased by for 
instance the inflammation status of individuals leading to variations in leukocyte 
composition. Furthermore, different amounts of platelets in the blood samples 
(platelets do not contain a nucleus but many mitochondria) potentially result in an 
overestimation of the mtDNA content in blood. 
We observed a heritability of only 35% indicating that environmental factors are 
supposed to play an important role in determining mtDNA content. This seems to 
be reflected by differences in mtDNA content in the independent study samples, 
used for this research. Although these differences may be partially caused by 
different DNA extraction techniques, it is also possible that biological differences 
between the samples have caused the variance in mtDNA content.  
Previous studies showing an association between mtDNA content in blood and 
type 2 diabetes or related traits are much smaller than our study and are therefore 
likely to be biased by sample selection. We conclude that mtDNA content in blood 
does not associate with type 2 diabetes or related traits in white European 
individuals. However, from our data we cannot draw the same conclusion for other 
tissues like muscle and liver. Several groups showed a relation between 
mitochondrial function and type 2 diabetes in patient muscle (6;7). This suggests 
that blood may not be the correct tissue for these analyses, but muscle tissue 
should be analyzed instead. However, mtDNA content in muscle depends on 
physical exercise adding an additional complexity. Patients with a sedentary life 
style, who are at risk for diabetes as a result of this life style, are therefore also 
expected to have lower mtDNA content in their muscles. This illustrates the 
complex nature of conclusions based on association. 
Others showed a decrease in mtDNA content in beta-cells upon ageing (25). This 
is of clinical importance since beta-cell function also declines during ageing and the 
decreasing mtDNA content is a plausible candidate mechanism. The beta-cell is 
therefore another important tissue to analyze, but difficult to obtain 
Remarkably, when an acute decline in mtDNA content of 30-50% is induced in 
humans, as result of highly active antiretroviral therapy (HAART), one observes a 
rapid development of insulin resistance and a more gradual steatosis of the liver, 
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both major risk factors for type 2 diabetes (26;27). However, this induced decrease 
in mtDNA content did not result in acute development of type 2 diabetes, indicating 
that pancreatic beta-cells seem to have a relatively large spare capacity in 
mitochondrial function.  
Taken together, the role of mtDNA content in the onset of type 2 diabetes awaits 
further investigation in different tissues. For predictive uses concerning type 2 
diabetes, mtDNA content in blood is not a useful parameter. 
As described in this discussion, we can not fully exclude that genetic variation in 
nuclear encoded mitochondrial proteins and variation in mtDNA content in blood is 
associated with type 2 diabetes. It is important that low frequency and rare genetic 
variation, CNVs and mtDNA content in different tissues are analyzed. However, 
one should also consider the possibility that mitochondrial dysfunction is not a 
common pathogenic mechanism for type 2 diabetes. Changes in mitochondrial 
parameters as described by others (6;7), might as well be caused by 
hyperglycemia, obesity or decreased exercise instead of being the pathogenic 
factor causing the disease. In fact, a study in diabetic Goto-Kakizaki rats provides 
evidence that mitochondrial oxidative capacity declines as a result of long-lasting 
metabolic dysfunction (24). Furthermore, Kelley et al showed that mitochondrial 
dysfunction is already present in obese subjects and further deteriorates when type 
2 diabetes develops (6). Another possibility is that mitochondrial dysfunction does 
increase type 2 diabetes susceptibility, but that this dysfunction is not caused by a 
defect in the mitochondrion itself but by factors controlling mitochondrial activity. 
For instance, it is known that calcium fluxes in- and outwards the mitochondrion 
plays an important role in glucose stimulated insulin secretion (GSIS). It might be 
possible that mitochondrial dysfunction is a result of impaired calcium signaling 
caused by for instance dysfunctional endoplasmic reticulum or disturbed GLP-1 
signaling, leading to decreased GSIS and subsequently type 2 diabetes (28). By 
this means, assessing causes of mitochondrial dysfunction directly, like decreased 
mtDNA content, would not result in the identification of increased type 2 diabetes 
susceptibility 
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Taken together, my personal interpretation of all the data is that genetic variation in 
mitochondrial components are not major contributors to the risk of an individual for 
diabetes. 
 
 
Part 3: Genes regulating fasting plasma glucose concentrations (chapter 5) 
Previously, SNPs in four genes have been shown to be associated with fasting 
plasma glucose (FPG) levels: GCK, GCKR, G6PC2 and MTNR1B (9;29-37). It is 
known that elevations in FPG levels within healthy range predicts a higher risk for 
type 2 diabetes and coronary heart disease later in life (38;39) 
For that reason I studied the analysis of the combined risk alleles of these 4 genes, 
on type 2 diabetes susceptibility. This study is described in chapter 5. SNPs were 
genotyped (rs1799884 (GCK), rs1260326 (GCKR), rs560887 (G6PC2) and 
rs10830963 (MTNR1B)) in a Dutch sample. I observed that these SNPs have a 
combined effect on FPG levels, which is also reflected by increased HbA1C. This 
finding confirms a previous observation in a French study (37). In addition, I also 
observed that the combined risk allele score of these genes is associated with a 
decreased type 2 diabetes susceptibility for those with a low number of risk alleles 
and with increased type 2 diabetes susceptibility for those with a high number of 
risk alleles, compared to individuals carrying the most common risk allele group (4 
risk alleles, 31% of the study sample). Furthermore, a high number of risk alleles 
also associates with a lower age at diagnosis of type 2 diabetes. This indicates that 
the known FPG genes have in combination an effect on type 2 diabetes 
susceptibility and age at diagnosis of type 2 diabetes as well, although their single 
gene effects are minimal or absent. Our data also suggest that the rate of increase 
of FPG concentrations upon ageing does not differ between individuals with a high 
number of risk alleles and those with a low number of risk alleles. This indicates 
that carriers of multiple risk alleles have an increased fasting glucose set point 
when compared to carriers of less risk alleles. Thus, it seems that these genetic 
variants determine the initial setting of the beta-cell glucose sensor, like the 
MODY2 polymorphisms in the glucokinase gene. A prospective study is needed to 
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strengthen this finding. The OGTT curve should than be increased over the entire 
length, as indicated in figure 2. This should be investigated in future research. 
Published studies have combined the risk alleles of all confirmed type 2 diabetes 
genes, resulting in a large difference in odds ratio between the extremes of the risk 
allele groups. Remarkably, the predictive value of genetic risk factors is limited 
compared to other non-genetic type 2 diabetes risk factors like age and BMI (40-
42). Therefore, the known genetic risk factors for type 2 diabetes do not improve 
the prediction of the disease when compared to anthropomorphic markers. 
Including the four FPG genes to the list of type 2 diabetes risk genes and analyzing 
the predictive value of the combined group of genes might further improve our 
understanding of the predictive value for the development of type 2 diabetes using 
known risk loci. Currently, it seems unlikely that common genetic variation will be 
useful as diagnostic predictor of type 2 diabetes. 
Until now, the best way to predict future type 2 diabetes risk, is by analyzing family 
history of type 2 diabetes, BMI and exercise level. It will be necessary to reveal all 
genetic risk factors for type 2 diabetes and related traits like FPG, BMI and insulin 
Figure 2. Predicted OGTT curves of low and high risk allele carriers 
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secretion in order to achieve a meaningful genetic prediction. This will go beyond 
the scope of common SNPs, since also low frequency (MAF = 0.01 - 0.05) and rare 
variation (MAF < 0.01) have to be analyzed. In addition, other variation like CNVs 
needs to be assessed. Therefore, resequencing has to be performed in order to 
analyze these forms of genetic variation. Since technology shows a quick 
development this will be possible in the near future. The hypothesis is that these 
forms of genetic variation will have a large impact on type 2 diabetes susceptibility. 
If this is true, this approach might prove to be useful in disease prediction. If the 
odds ratio’s of these genetic variations will be in the same range as those of 
common SNPs (OR between 1.1 and 1.3) the additive value will be little and 
studies will be easily underpowered to detect such associations. Future research 
will shed more light on these important issues. 
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Closing remarks 
Until recently genetic research related to type 2 diabetes has struggled to prove its 
use in medical science. Only sparsely novel type 2 diabetes genes were identified. 
The studies described in this thesis again underline the difficulties one can 
encounter during the search for such diabetes risk genes, since we could not 
identify any novel type 2 diabetes gene by the candidate-gene approach. However, 
with the coming of GWAS, new hope emerged for genetic research since it 
identified several new loci in relatively short time. Unfortunately, until now no 
functional polymorphism has been identified and no major type 2 diabetes loci with 
large impact on disease risk have been depicted. Since the known type 2 diabetes 
loci do not have a significant predictive value for type 2 diabetes, the clinical 
relevance of type 2 diabetes genetic research is under fire. The hope was that by 
identification of high risk individuals for diabetes, progression of the disease could 
be specifically prevented in those individuals by early therapeutic intervention. Until 
now, this is not possible. Only by further genetic research, like assessing effect 
sizes of low frequency variation, rare variation and CNVs as described above, the 
value of genetic research can be clarified. Therefore, further investments in genetic 
research will be needed.  
Although it is difficult to link the genetic variations in the various diabetes risk genes 
with a particular pathogenic mechanism, the genes in which these variants occur 
are often related to the function of the beta cell rather than with insulin action. This 
suggests that the onset of decreased insulin secretion has a large genetic 
compound, while insulin resistance is induced predominantly by influences like diet, 
exercise and ageing. This has contributed to a change in view on the pathogenesis 
of the disease as previously it was considered that insulin resistance as a result of 
a genetic predisposition was the driving factor for the pathogenesis of type 2 
diabetes. However, another possibility might be that the current design of studies is 
not suitable to detect insulin resistance genes. If low frequency and rare variants 
and CNVs do have an impact on insulin resistance, they will be identified in the 
coming years. Furthermore, GWAS have identified susceptibility genes, which are 
not likely to be selected by candidate gene approach since their function was 
unknown or not involved in a likely type 2 diabetes pathogenic pathway. This is one 
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of the important benefits of the hypothesis-free approach of GWAS and provides 
more insight in the pathogenic pathway of type 2 diabetes. Therefore, genetics of 
type 2 diabetes already showed its use in the past and future research will 
hopefully further improve our understanding of type 2 diabetes. 
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Type 2 diabetes is een chronische ziekte, waarvan het voorkomen wereldwijd fors 
toeneemt. De ziekte wordt gekarakteriseerd door chronisch verhoogde glucose 
spiegels, wat op den duur kan resulteren in glucose geïnduceerde complicaties 
zoals schade aan bloedvaten en het zenuwstelsel. Daarnaast kan de ziekte leiden 
tot cardiovasculaire aandoeningen waardoor de levensverwachting van type 2 
diabetes patiënten met ongeveer 10 jaren afneemt. De ziekte ontstaat onder 
andere door een verminderde reactie van de lever, spier- en vetweefsel op 
insuline. In combinatie met een verminderd vermogen van de pancreas om insuline 
uit te scheiden, resulteert dit in verhoogde glucose spiegels. Bij een glucose 
waarde boven de 7 mmol/L in nuchtere conditie, is er sprake van type 2 diabetes. 
Het is bekend dat factoren zoals overgewicht, weinig beweging en veroudering het 
risico op type 2 diabetes verhogen. Verder speelt ook genetische variatie een rol in 
de vatbaarheid voor deze ziekte. Het is echter nog niet geheel duidelijk welke 
genen hierbij een rol spelen en hoe groot de invloed van deze genen is op de 
vatbaarheid voor type 2 diabetes. In deze studie heb ik geprobeerd om meer 
helderheid te krijgen in de rol van genetische variatie bij het ontstaan van type 2 
diabetes. 
 
Het eerste gedeelte van deze studie is gewijd aan genen die betrokken zijn bij 
mitochondriële functie. Mitochondriën spelen een belangrijke rol bij het glucose 
metabolisme, insuline secretie en vetzuurverbranding en er is op grond hiervan 
gesuggereerd dat een slechte mitochondriële functie kan leiden tot type 2 diabetes. 
In totaal heb ik 14 kandidaat-genen geselecteerd, die allemaal een belangrijke rol 
spelen in het onderhouden van een goede mitochondriële functie. Alle 
geselecteerde genen worden gecodeerd door het nucleaire DNA en de eiwitten 
worden vervolgens geïmporteerd in het mitochondrion. Met behulp van de 
internetdatabase HapMap (www.hapmap.org) heb ik een selectie gemaakt van 
zogenaamde ‘single nucleotide polymorphisms’ (SNP’s), waarmee alle veel 
voorkomende variatie (frequentie > 5%) geanalyseerd kan worden. Al deze SNP’s 
zijn gemeten in de Nederlandse Hoorn studie (n = 999), dit is de eerste fase van dit 
project. Vervolgens zijn de SNP’s die statistisch bewijs vertoonden voor een 
associatie met type 2 diabetes (p < 0.05), opnieuw gemeten in drie andere 
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Nederlandse studies (Nieuwe Hoorn Studie, ERGO studie en Breda studie). Dit is 
de tweede fase van deze studie (n = 10164). Het doel van deze tweede fase is het 
bevestigen van potentiële associaties om toevalsbevindingen uit te sluiten. Slechts 
één SNP toonde na deze tweede fase zwak bewijs voor een associatie met type 2 
diabetes (p = 0.01). Echter, nadat we de tweede fase hadden uitgebreid met een 
studie uit Denemarken (n = 1220), bleef dit niet statistisch significant (p = 0.06). Dit 
betekent dat veelvoorkomende variatie in onze kandidaat genen niet een rol speelt 
bij het ontstaan van type 2 diabetes. Tijdens afronding van deze studie, 
verschenen er verschillende genome wijde associatie studies (GWAS). GWAS 
worden gebruikt om veel voorkomende variaties verspreid over het gehele genoom 
te associëren met een bepaald fenotype (in dit geval type 2 diabetes). Resultaten 
van deze GWAS bevestigden onze negatieve bevindingen en toonden verder aan 
dat variatie in andere mitochondriële genen waarschijnlijk ook geen belangrijke rol 
spelen bij het ontstaan van type 2 diabetes. 
 
In het tweede gedeelte van dit onderzoek, hebben we onderzoek gedaan naar het 
mitochondriële DNA (mtDNA). Dit is een klein circulair genoom in het 
mitochondrion, wat in verschillende hoeveelheden in de cel voorkomt. Omdat in het 
verleden in kleine studies is aangetoond dat een lage hoeveelheid mtDNA 
geassocieerd is met een verhoogd risico op type 2 diabetes, hebben wij dit verder 
onderzocht. Allereerst hebben we de erfelijkheid van de hoeveelheden mtDNA 
onderzocht, gebruik makende van het Nederlandse Tweelingen Register. Dit leidde 
tot de conclusie dat de hoeveelheid mtDNA voor ongeveer 35% wordt bepaald 
door genetische factoren. Vervolgens hebben we onderzocht of de hoeveelheden 
mtDNA ook effect hebben op de vatbaarheid voor type 2 diabetes. Hiervoor 
hebben we een zogenaamde case / control studie gebruikt uit de regio van Hoorn, 
waarbij mensen met en zonder type 2 diabetes met elkaar vergeleken worden. 
Verder gebruikten we twee prospectieve studies, waarbij voor een groep gezonde 
mensen voor een bepaalde periode wordt bijgehouden of ze type 2 diabetes 
hebben ontwikkeld. Bij geen van deze studies hebben we aanwijzingen gevonden 
dat variaties in hoeveelheden mtDNA het risico op type 2 diabetes beïnvloeden. 
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Onze conclusie is daarom dat verlaagde hoeveelheden mtDNA niet tot verhoogde 
vatbaarheid voor type 2 diabetes leiden, wat eerder wel gesuggereerd was. 
 
In het derde gedeelte van dit proefschrift beschrijf ik het onderzoek naar de relatie 
tussen verschillende genen en ‘fasting plasma glucose’ (FPG) concentratie. Tot op 
heden is er van vier genen reproduceerbaar aangetoond dat zij de FPG 
concentratie beïnvloeden. Dit zijn de genen GCK, GCKR, G6PC2 en MTNR1B. In 
deze studie heb ik SNP’s in de genoemde genen (1 SNP per gen, op basis van 
eerder gepubliceerde resultaten van andere groepen) gemeten in een groep 
mensen met en zonder type 2 diabetes uit de regio van Hoorn. Omdat er bij het 
analyseren van 1 variant sprake is van een spreiding van 0 tot en met 2 risico 
allelen, is er bij 4 varianten sprake van een spreiding van 0 tot en met 8 risico 
allelen. Door middel van het optellen van het aantal risico allelen van ieder 
individu, was het mogelijk om een risico allel score te berekeningen en het effect 
van deze score op FPG concentraties en type 2 diabetes vatbaarheid te 
analyseren. Het bleek dat individuen die een hoge score hebben, niet alleen 
verhoogde FPG concentraties hebben, maar ook een hogere vatbaarheid voor 
type 2 diabetes vergeleken met mensen met een gemiddelde score. Verder lieten 
deze resultaten ook zien dat type 2 diabetes patiënten met een hoge score, 
gemiddeld eerder de ziekte ontwikkelden, ten opzichte van patiënten met een 
gemiddelde score. 
 
Samenvattend konden wij geen genetische defecten ontdekken in nucleair 
gecodeerde mitochondriële genen en verschillen in hoeveelheden mtDNA die de 
vatbaarheid op type 2 diabetes beïnvloeden. Deze data wijzen erop dat 
mitochondriële disfunctie wellicht minder belangrijk is bij het ontstaan van type 2 
diabetes dan eerder verondersteld. Mogelijk is mitochondriële disfunctie een 
gevolg van type 2 diabetes en niet andersom. Echter, dit onderzoek beslaat alleen 
maar veel voorkomende genetische variatie en mtDNA in bloed. Het is belangrijk 
dat in de toekomst ook minder frequentie genetische variatie en hoeveelheden 
mtDNA in andere weefsels worden onderzocht. Verder is het mogelijk dat niet 
genetische factoren mitochondriële functie verstoren en op deze manier type 2 
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diabetes risico verhogen. Een hypothese is bijvoorbeeld dat factoren zoals 
overgewicht, veroudering of weinig lichamelijke activiteit een negatief effect hebben 
op mitochondriële functie en zodoende de vatbaarheid voor type 2 diabetes 
verhogen. Verder blijkt uit onze data dat genen die FPG concentraties beïnvloeden 
gezamenlijk ook de vatbaarheid van type 2 diabetes beïnvloeden. 
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